Fitness and Cardiovascular Risk Factors – What Everyone Should Know

Linda Landini, MD
Department of Internal Medicine, University of Pisa, Pisa, Italy

Aurelio Leone, MD
Fellow of the Royal Society for Promotion of Health, Castelnuovo Magra, Italy

Series: Physical Fitness, Diet and Exercise
BISAC: HEA039080, MED010000

Clear

$179.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Fitness is a widespread practice especially in Western countries and is being investigated in several respects from a scientific and health perspective as well as its role in obtaining a pleasing physical appearance. The authors discuss fitness as a recreational hobby. Since physical fitness includes exercises that require adequate preparation and not completely without risk to one’s health, it is essential that those practitioners are made aware of both the basic principles of fitness and the potential adverse effects associated with it. This is true primarily when cardiovascular risk factors are concerned. The purpose of this book is to describe these topics in a concise way with suggestions for understanding the subject. (Imprint: Nova)

Preface

Biography of the Authors

Chapter 1. The Role of Fitness in Performing an Exercise

Chapter 2. Physiological Response to Exercise

Chapter 3. Fitness Devices Related to the Cardiovascular System

Chapter 4. Impact of Fitness on Population Health

Chapter 5. Cardiovascular Risk Factors

Chapter 6. Smoking

Chapter 7. Hypertension

Chapter 8. Metabolic Disorders

Chapter 9. Obesity and Fitness

Chapter 10. Lifestyle and Fitness

Chapter 11. Final Remarks

Index

Chapter 1

[1] U.S. Department of Health and Human Services. Physical activity and health: a report of the Surgeon General, Atlanta: U.S. Department of Health and Human Services. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, 1996.
[2] Leenders KL, Perani D, Lammertsma AA, et al. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain 1990; 113 (1): 27-47.
[3] Saltin B, Blomqvist G, Mitchell JH, et al. A longitudinal study of adaptive changes in oxygen transport and body composition. Circulation 1968; 38 (1): 1-78.
[4] Chance B, Leigh JS Jr, Clark BJ, et al. Control of oxidative metabolism and oxygen delivery in human skeletal muscle: A steady-state analysis of the work/energy cost transfer function. Proc Natl Acad Sci. USA 1985; 82: 8384-8388.
[5] Leone A. Health of exposed individuals. In: Passive Smoking and Cardiovascular Pathology. Mechanisms and Physiopatholgical Bases of Damage, A. Leone Ed., 2nd edition, Cardiology Research and Clinical Development, Nova Biomedical, Nova Science Publishers, Inc, New York, USA; 2012: 10-12.
[6] Glantz SA. Air pollution as a cause of heart disease: Time for action. J. Am. Coll Cardiol 2002; 39: 943-5.
[7] Haskell WL. Primer in Preventive Cardiology. In: Pearson TA, et al. Eds, American Heart Association, Dallas, USA 1994: 173-87.
[8] Parer JT, Metcalfe J. Oxygen transport by oxygen in relation to body size. Nature 1967; 215: 653-4.
[9] Fan FC, Chen RY, Schuessler GB, Chien S. Effects of hematocrit variations on regional hemodynamics and oxygen transport in the dog. Am J Physiol (Heart and Circulatory Physiology) 1980; 238 (4): H545-H552.
[10] Page TC, Light RW, McKay GB, Hellums DJ. Oxygen transport by erythrocyte/hemoglobin solution mixtures in an in-vitro-capillary as model of hemoglobin-based oxygen carrier performance. Microvasc Res 1998; 55 (1): 54-64.
[11] Kelman GR. Digital computer subroutine for the conversion of oxygen tension into saturation. J. Appl Physiol 1966; 21 (4): 1375-6.
[12] Severinghaus JW. Simple, accurate equations for human blood O2 dissociation computations. J Appl Physiol (Respir Environ Exercise Physiol) 1979; 46 (3): 599-602.
[13] Lawson JW, Veech RL. Effects of PH and free Mg2+ on the Keq of the creatine chinase reaction and other phosphate hydrolyses and phosphate transfer reactions. J. Biol. Chem 1979; 254: 6528-37.
[14] Wasserman K. The anaerobic threshold measurement to evaluate exercise performance. Am. Rev. Respir. Dis 1984; 129, Suppl: S35-S40.
[15] Porcari JP, Foster C, Schneider P. Exercise response to elliptical trainers. Fitness Management 2000; August: 50-3.
[16] Sweitzer ML, Kravitz L, Weingart HM, et al. The cardiopulmonary responses of elliptical cross training versus treadmill walking in CAD patients. J. Exercise Physiol 2002;5 (4): 11-5.
[17] Dalleck LC, Kravitz L, Robergs A. Maximal exercise testing using the elliptical crosstrainer and treadmill. J. Exercise Physiol 2004; 7 (3): 94-101.
[18] Bergh U, Kanstrup L, Ekblom B. Maximal oxygen uptake during exercise with various combinations of arm and leg work. J. Appl. Physiol 1976; 41: 191-6.
[19] ACSM’s Guidelines for exercise stress testing and prescription, 7th edition, Lippincot Williams&Wilkins, Philadelphia, U.S.A., 2006..
[20] Spin JM, Prakash M, Froelicher VF, et al. The prognostic value of exercise testing in elderly men. Am. J. Med 2002; 112: 453-9.
[21] Morris CK, Myers J, Kawaguchi T, et al. A normogram based on metabolic equivalents and age for aerobic exercise capacity in men. J. Am. Coll Cardiol 1993; 22: 175-82.
[22] Froelicher VF, Fearon V, Ferguson C, et al. Lessons learned from studies of the standard exercise test? Chest 1999; 116: 1442-51.
[23] Cole CR, Blackstone EK, Pashkow FJ, et al. Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl. J. Med 1999; 341: 1351-7.
[24] Shetler K, MarkusR, Froeliker VF, et al. Heart rate recovery: Validation and methodologic issues. J. Am. Coll Cardiol 2001; 38: 1980-7.
[25] Farber JL, Chien KR, Mitnnacht S. The pathogenesis of irreversible cell injury in ischemia. Am. J. Pathol 1981; 102: 171-81.
[26] Venkatachalam MA, Kreisberg JL, Stein JH, Lifschitz MD. Salvage of ischemic cells by impermeant solute and ATP. Lab Invest 1983; 49: 1-3.
[27] White A., Handler P., Smith EL. Biological oxidation II. In Principles of Biochemistry, A White et al. eds, 4th edition, McGraw-Hill Book Company, New York, Sidney, Toronto, London, 1968: 321-54.
[28] Cowley G. The biology of beauty. Newsweek 1966; 127: 60-7.
[29] Little A, Perret D. Putting beauty back in the eye of the beholder. Psychologist 2002; 15: 28-32.
[30] Langlois JH, Kalakanis L, Rubenstein AJ, et al. Maxims or myths of beauty? A meta-analytic and theoretical review. Psychological Bulletin 2000; 126: 390-423.
[31] Huxley HE. The double array of filaments in cross-striated muscle. J. Biophys Biochem Cytol 1957; 3: 631-48.
[32] Huxley HE. Electron microscope studies on the structure of natural and synthetic protein filaments from striated muscle. J. Mol. Biol 1963; 7: 281-308.
[33] Stonnington HH, Engel AE. Normal and denervated muscle. Neurology 1973; 23:
714-24.
[34] Hoppeler H, Howald H, Conley K, et al. Endurance training in humans: aerobic capacity and structure of skeletal muscle. J. Appl. Physiol 1985; 59 (2): 320-7.
[35] Huxley HE. The mechanism of muscular contraction. Scient Amer 1965; 213: 18-27.
[36] Adrian ED, Bronk DW. The discharge of impulses in motor nerve fibers. Part II. The frequency of discharge in reflex and voluntary contractions. J. Physiol 1928; 67, Part II.
[37] Sandow A. Excitation-contraction coupling in muscular response. Seminar in Pharmacology at the Yale University School of Medicine, Ma1 1; 1952.
[38] Orkand RK. The relation between membrane potential and contraction in single crayfish muscle fibers. J. Physiol 1962; 161 (1): 143-59.
[39] McKenna M. The roles of ionic processes in muscular fatigue during intense exercise 1. Sports Medicine 1992; 13 (2): 134-45.
[40] Thyfault JP, Cree MG, Tapscott EB, et al. Metabolic profiling of muscle contraction in lean compared with obese rodents. Am. J. Physiol. Regul. Integr Comp Physiol 2010; 299 (3): R926-R 934.
[41] Angelika PC, Rosenthal N. Different modes of hypertrophy in skeletal muscle fibers. J. Cell Biol. 2002; 156 (4): 751-60.
[42] Fox KR. The influence of physical activity on mental well-being. Public Health Nutrition 1999; 2 (Suppl 3): 441-8.
[43] Scheier MF, Carver CS. Effects of optimism on psychological and physical well-being. Theoretical overview and empirical update. Cog. Ther and Res 1992; 16 (2): 201-28.
[44] Scheier MF, Weintraub JK, Carver CS. Coping with stress: Different strategies of optimists and pessimists. J. Pers. Soc Psychol 1986; 51: 1257-64.
[45] Folkman S, Lazarus RS. An analysis of coping in the middle-aged community sample. J. Health Soc Behav 1980; 21: 219-39.
[46] Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: A theoretically based approach. J. Pers Soc. Psychol 1989; 56. 267-83.
[47] Taylor SE, Kemeny ME, Aspinwall LG, et al. Optimism, coping, psychological distress, and high-risk sexual behavior among men at risk for AIDS. J. Pers Soc Psycol 1992; 61 (3): 460-73.
[48] Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: Risk of cardiovascular disease and preventive measures. Curr. Pharm. Des. 2003; 9 (29): 2417-23.
[49] Myers J. Exercise and cardiovascular health. Circulation 2003; 107: e2-e5.
[50] Lavie CJ, Thomas RJ, Squires RW, et al. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin. Proc 2009; 84 (4): 373-83.
[51] World Health Organization (WHO). The World Health Report 2002: Reducing risk, promoting healthy life. Geneva, 2002.

Chapter 2

[1] Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: Risk of cardiovascular disease and preventive measures. Curr. Pharm. Des. 2003; 9:2417-23.
[2] Koch-Weser J, Blinks JR. The influence of the interval between beats on myocardial contractility. Pharmacol Rev 1963; 15: 601-52.
[3] Sonnenblick EH, Morrow AG, Williams JF Jr. Effect of heart rate on the dynamics of force development in the intact human ventricle. Circulation 1966; 33: 945-51.
[4] Mahler F, Ross J Jr, O’Rourke RA, Covell JW. Effects of changes in preload, afterload and inotropic state on ejection and isovolumic phase measures of contractility in the conscious dog. Am. J. Cardiol. 1975; 35: 626-34.
[5] Mahler F, Yoran C, Ross J Jr. Inotropic effect of tachycardia and poststimulation potentiation in the conscious dog. Am. J. Physiol 1974; 227: 569-75.
[6] Sonnenblick EH, Strobeck JE. Derived indices of ventricular and myocardial function. N. Engl. J. Med. 1977; 296: 978-82.
[7] Fletcher GF, Flipse TR, Oken KR. Exercise and Cardiovascular System. In: Hurst’s The Heart, 11 TH Edition, Fuster V et al. eds, Mc-Graw-Hill Medical Publishing Division, New York, USA, 2004; 2245-53.
[8] Leone A. Physiology of the coronary circulation. In: Coronary Circulation in Nonsmokers and Smokers. A. Leone ed., Nova Biomedical, Nova Biomedical Books, New York, USA, 2008; 21-41.
[9] Dahlstrom A, Fuxe F, Mya-tu M, Zetterstrom BEM. Observation on adrenergic innervation of the dog heart. Am. J. Physiol 1965; 209: 689-92.
[10] Woollard HH. Innervation of the heart. J. Anat 1926; 60: 345-73.
[11] Leone A. Interactive effect of combined exposure to active and passive smoking on cardiovascular system. Recent Pat Cardiovasc Drug Discov 2011; 6: 61-9.
[12] Axelrod J. The metabolism, storage and release of catecholamines. Recent progr Hormon Res. 1965; 21: 597-622.
[13] Chalmers JP, West MJ. The nervous system in the pathogenesis of hypertension. In: Robertson JIS ed., Handbook of hypertension: Clinical Aspects of Essential Hypertension. Elsevier, Amsterdam, Neth, 1983, 1: 64-96.
[14] Calaresu FR, Yardley CP. Medullary basal sympathetic tone. Ann. Rev. Physiol 1988; 50: 511-24.
[15] Anton AH, Sayre DF. A study of the factors affecting the aluminium oxide-trihydroxyndole procedure for the analysis of catecholamines. J. Pharmacol. Exp. Ther 1966; 138: 360-74.
[16] Hasking GJ, Esler MD, Jennings JL, et al. Norepinephrine spillover to plasma during steady-state supine bicycle exercise. Circulation 1988; 78: 516-21.
[17] Riegger AJG, Liebau G. The renin-angiotensin-aldosterone system, antidiuretic hormone and sympathetic nerve activity in an experimental model of congestive heart failure in the dog. Clin. Sci. 1982; 62: 465-9.
[18] Breuer HW, Skyschally A, Schulz R, et al. Heart rate variability and circulating catecholamine concentrations during steady state exercise in healthy volunteers. Br. Heart J. 1993; 70: 144-9.
[19] Leone A. Functional disorders of the cardiovascular system. In: Passive Smoking and Cardiovascular Pathology. Mechanisms and Physiopathological Bases of Damage. A Leone ed., 2nd edition, Cardiology Research and clinical Developments, Nova Biomedical, Nova Science Publishers, Inc., New York, USA, 2012;103- 17.
[20] Fagard R, M’Buyamba-Kabangu JR, Staessen J, et al. Physical activity and blood pressure. In: Bulpitt CJ ed., Handbook of Hypertension Vol 6, Elsevier, Amsterdam, Neth, 1985; 104-30.
[21] Fagard R. Habitual physical activity, training and blood pressure in normo- and hypertension. Int. J. Sport. Med. 1985; 6: 57-67.
[22] Amery A, Julius S, Whitlock LS, Conway J. Influence of hypertension on the haemodynamic response to exercise. Circulation 1967, 36: 231-7.
[23] Asmussen E. Similarities and dissimilarities between static and dynamic exercise. Circ. Res. 1981; 48 (Suppl I): I-3 I-10.
[24] Bruce RA, Fisher LD, Cooper MN, Gey GO. Separation of effects of cardiovascular disease and age on ventricular function with maximal exercise. Am. J. Cardiol. 1974; 34: 757-63.
[25] Landini L, Leone A. Smoking and hypertension: Effects on clinical, biochemical and pathological variables due to isolated or combined action on cardiovascular system. Curr. Pharm. Des. 2011; 17: 2987-3001.
[26] Landini L, Lambelet P, Taccola D, et al. Blood Pressure and Cardiovascular Comorbidity in Chronic Heart Failure of Ageing. JCH 2013;
[27] Opie CH. Sudden death and sport. Lancet 1975; 1: 263-6.
[28] Thompson PD, Stern MP, Williams P, et al. Death during jogging and running. JAMA 1979; 242: 1265-7.
[29] Waller BF, Roberts WC. Sudden death while running in conditioned runners aged 40 years or over. Am. J. Cardiol 1980; 45: 1292-300.
[30] Virmani R, Robinowitz M, McAllister HA. Non-traumatic death in joggers. Am. J. Med. 1982; 72; 874-82.
[31] Maron BJ, Roberts WC, McAllister HA, et al. Sudden death in young athletes. Circulation 1980, 62: 218-29.
[32] Siskovich DS, Weiss NS, Fletcher RH, et al. The incidence of primary cardiac arrest during vigorous exercise. N. Engl. J. Med. 1984; 311: 874-8.
[33] Martin WD, Montgomery J, Snell PG, et al. Cardiovascular adaptations to intense swim training in sedentary middle-aged men and women. Circulation 1987; 75: 323-30.
[34] Jennings J, Nelson L, Nestel P, et al. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. Circulation 1986; 73: 30-40.
[35] deVries HA. Physiological effects on an exercise training regimen upon men aged 52-88. J. Gerontol. 1970; 25: 325-36.
[36] Hagberg JM, Goldring D, Ehsani AA, et al. Effect of exercise training on the blood pressure and hemodynamic features of hypertensive adolescents. Am. J. Cardiol 1983; 52: 763-8.
[37] Urata H, Tanabe Y, Kiyonaga A, et al. Antihypertensive and volume-depleting effects of mild exercise on essential hypertension. Hypertension 1987; 9. 245-52.
[38] Kinoshita A, Urata H, Tanabe Y, et al. What types of hypertensives respond better to mild exercise therapy? In: Abstract book of the 12th Scientific Meeting of the International Society of hypertension 1988; 420.
[39] Nelson L, Jennings JL, Esler MD, Korner PI. Effect of changing levels of physical activity on blood pressure and haemodynamics in essential hypertension. Lancet 1986; 2: 473-6.
[40] Péronnet F, Cléroux J, Perrault H, et al. Plasma norepinephrine response to exercise before and after training in humans. J. Appl. Physiol. 1981; 51: 812-5.
[41] Winder WW, Hickson RC, Hagberg JM, et al. Training-induced changes in hormonal and metabolic responses to submaximal exercise. J. Appl. Physiol. 1979; 46: 766-71.
[42] Ekblom B, Kilbom A, Soltysiak J. Physical training, bradycardia and autonomic nervous system. Scand J. Lab Invest 1973; 32: 251-4.
[43] Hartley LH, Mason JW, Hogen RP, et al. Multiple hormonal responses to prolonged exercise in relation to physical training. J. Appl. Physiol. 1972; 33: 607-10.
[44] M’Buyamba-Kabangu JR, Fagard R, Lijnen P, Amery A. Relationship between plasma renin activity and physical fitness in normal subjects. Eur. J. Appl. Physiol. 1985; 53: 304-7.
[45] Viinika L,Vuori J,Ylikorkala O. Lipid peroxides, prostacyclins and thromboxane A2 in runners during acute exercise. Med. Sci. Sports Exerc 1984; 16: 275-7.
[46] Boutellier U, Piwko P. The respiratory system as an exercise limiting factor in normal sedentary subjects. Eur. J. Appl. Physiol 1992; 64: 145-52.
[47] Anholm JD, Stray-Gundersen J, Ramanathan M, Johnson RL Jr. Sustained maximal ventilation after endurance exercise in athletes. J. Appl. Physiol 1989;67:1759-63.
[48] Boutellier U, Buchel R, Kundert A, Spengler C. The respiratory system as an exercise limiting factor in normal trained subjects. Eur. J. Appl. Physiol. 1992; 65: 347-53.
[49] The Free Dictionary by FARLEX Online.
[50] Leith DE, Bradley M. Ventilatory muscle strength and endurance training. J. Appl. Physiol 1976; 41: 508-16.
[51] Belman MS, Gaesser GA. Ventilatory muscle training in the elderly. J. Appl. Physiol 1988; 64: 899-905.
[52] Morgan DW, Kohrt WM, Bates BJ, Skinner JS. Effects of respiratory muscle endurance training on ventilatory and endurance performance on moderately trained cyclists. Int. J. Sports Med. 1987; 8: 88-93.
[53] Sheller JR. Asthma: Emerging concepts and potential therapies. Am. J. Med. Sci. 1987; 293: 298-308.
[54] Campbell NA, Reece JB. Biology, 7th edition, Benjamin Cummings Publisher, Pearson Education, Los Angeles, USA, 2005.
[55] Horecker BL. Alternative pathways of carbohydrate metabolism and their physiological significance. J. Chem. Education 1965; 42: 244 – 5 3.
[56] Ashwell G. Carbohydrate metabolism. Ann. Rev. Biochem. 1964; 33: 101 – 38.
[57] Mokdad, A.H., Bowman, B.A., Ford, E.S., et al. Prevalence of obesity, diabetes, and obesity related health risk factors. JAMA 2003, 289;76-79.

Chapter 3

[1] Fletcher GF, Balady GJ, Amsterdam EA, et al. Exercise standards for testing and training: A statement for healthcare professionals from the American Heart Association. Circulation 2001; 104: 1694-740.
[2] Hambrecht RP, Schuler GC, Muth T, et al. Greater diagnostic sensitivity of treadmill versus cycle exercise testing of asymptomatic men with coronary artery disease. Am. J. Cardiol 1992; 70: 141-6.
[3] Myers J, Buchanan N, Walsh D, et al. A comparison of the ramp versus standard exercise protocols. J. Am. Coll Cardiol. 1991; 17: 1334-42.
[4] Froelicher VF, Lehmann KG, Thomas R, et al. The electrocardiographic exercise test in a population with reduced workup bias: Diagnostic performance, computerized interpretation, and multivariable prediction. Ann. Intern Med. 1998; 128: 965-74.
[5] Nosratian F, Froelicher VF. ST elevation during exercise stress testing: A review. Am. J. Cardiol 1989; 63: 986-8.
[6] Spin JM, Prakash M, Froelicher VF, et al. The prognostic value of exercise stress testing in elderly men. Am. J. Med 2002; 112: 453-9.
[7] Leone A, Mori L, Bertanelli F, Fabiano P, Filippelli M. Indoor passive smoking: Its effect on cardiac performance. Int. J. Cardiol 1991; 8: 247-52.
[8] Eliot RS, Baroldi G, Leone A. Necropsy studies in myocardial infarction with minimal or no coronary luminal reduction due to atherosclerosis. Circulation 1974; 49: 1127-31.
[9] Leone A. Cardiovascular damage from smoking: A fact or belief? Int J Cardiol 1993; 38: 113-7. 10.
[10] Parthington S, Cho S, Myers J, et al. Prevalence and prognostic value of exercise-induced ventricular arrhythmias. Am. Heart J. 2003; 145: 139-46.
[11] Leone A, Bertanelli F, Mori L, Fabiano P, Bertoncini G. Ventricular arrhythmias by passive smoking in patients with preexisting myocardial infarction. J. Am. Coll Cardiol 1992; 3: 256 (A).
[12] Prakash M, Myers J, Froelicher VF, et al. Clinical and exercise test predictors of all-cause mortality: Results from >6,000 consecutive referred male patients. Chest 2001; 120: 1003-13.
[13] Debbas NMG, Jackson SHD, de Jonghe D, et al. Human atrial depolarization: Effects of sinus rate, pacing and drugs on the surface electrocardiogram. J. Am. Coll Cardiol 1999; 33: 358 –65.
[14] Markides V, Schilling RJ, Ho SY, et al. Characterization of left atrial activation in the intact human heart. Circulation 2003; 107: 733-9.
[15] Pellicia A, Maron BJ, Culasso F, et al. Clinical significance of abnormal electrocardiographic patterns in trained athletes. Circulation 2000; 102: 278-84.
[16] Akselrod S, Gordon D, Ubel AF, et al. Power spectrum analysis of heart rate fluctuation: A quantitative probe of beat-to-beat cardiovascular control. Science 1981; 4504: 220-2.
[17] Robinson BF, Epstein SE, Beiser DG, Braunwald E. Control of heart rate by the autonomic nervous system – Studies in man on the interrelation between baroceptor mechanisms and exercise. Circ Res 1966; 19: 400-11.
[18] Holmgren A, Mattsson KH. A new ergometer with constant work load at varying pedalling rate. Scand J. Clin. Lab Inv 1954; 6 (2): 137-40.
[19] Hull ML, Davis RR. Measurement of pedal loading in bicycling: I. Instrumentation. J. Biomech 1981; 14 (12): 843-55.
[20] Newmiller J, Hull ML, Zajac FE. A mechanically decoupled two force component bicycle pedal dynamometer. J. Biomech 1988; 21 (5): 375-9.
[21] Kautz SA, Hull ML. Dynamic optimization analysis for equipment setup problems in endurance cycling. J. Biomech 1995; 28 (11): 1391-401.
[22] Andrews RJ. Treadmill for small laboratory animals. J. App. Physiol 1965; 20 (3):
572-4.
[23] Pearce ME, Cunningham DA, Donner AP, et al. Energy cost of treadmill and floor walking at self-selected forces. Eur. J App Physiol 1983; 52: 115-9.
[24] Roepstorff L, Johnston C, Drevemo S. The influences of different treadmill construction on ground reaction forces as determined by the use of a force-measuring horseshoe. Equine. Vet J. 1994; 26 (17): 71-4.
[25] Zhang Y, He P. Research and development of measuring equipment for treadmill energy transfer. Adv. Mater Research 2013; 650: 431-6.
[26] Correia LCL, Lakatta EG, O’Connor FC, et al. Attenuated cardiovascular reserve during prolonged submaximal cycle exercise in healthy older subjects. J. Am. Coll Cardiol 2002; 40: 1290-7.
[27] Fletcher GF, Flipse TR, Kligfield P, et al. Current status of ECG stress testing. Curr. Probl. Cardiol 1998; 23: 353-423.
[28] Jones NL, Makrides L, Hitchcoock C, et al. Normal standards for an incremental progressive cycle ergometer test. Ann. Rev. Respir. Dis 1985; 131: 700-8.
[29] Sue DY, Hansen JE. Normal values in adults during exercise stress testing. Clin. Chest Med 1984; 5: 89-98.
[30] Neder JA, Nery LE, Castelo A, et al. Prediction of metabolic and cardiopulmonary responses to maximum cycle ergometry: a randomised study. Eur. Respir J. 1999; 14: 1304-13.
[31] Zhang YY, Johnson MC 2nd, Chow N, Wasserman K. Effect of exercise testing protocol on parameters of aerobic function. Med. Sci. Sports Exerc. 1991; 23: 625-30.

Chapter 4

[1] Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference, New York, 19-22 June, 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948.
[2] Dearden L, Reed H, Van Reenen J. The impact of training on productivity and wages: evidence from British panel data. The Oxford Bulletin of Economics and statistics 2006, 68 (4): 397-421.
[3] Morris J. The role of exercise in the prevention of coronary heart disease: today’s best buy in public health. Med&Science in Sport&Exercise 1994; 26: 807-13.
[4] World Health Organization (WHO). Global Health Risks: Mortality and Burden of Disease Attributable to Selected Major Risks. Geneva, WHO, 2009.
[5] Lee IM, Shiroma EJ, Lobelo F, et al. for the Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 2012; 380: 219-29.
[6] Leone A, Landini L, Leone A. Epidemiology and costs of hypertension-related disorders. Curr. Pharm Des. 2011; 17: 2955-72.
[7] Olshansky SJ, Ault AB. The fourth stage of epidemiologic transition: The age of delayed degenerative diseases. Milbank Q 1986; 64: 355-91.
[8] Omran AR. The epidemiologic transition: A key of the epidemiology of population change. Milbank Mem Fund Q 1971; 49: 509-38.
[9] Williams CL, Hayman LI, Daniels SR, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young. American Heart Association. Circulation 2002; 106: 143-60.
[10] Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: risk of cardiovascular disease and preventive measures. Curr. Pharm Des 2003; 9: 2417-23.
[11] Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995, 273 (5): 402-7.
[12] Brown SG, Rhodes RE. Relationships among dog ownership and leisure-time walking in Western Canadian adults. Am. J. Prev. Med. 2006;30(2):131-6.
[13] WHO/EC Project on monitoring progress on improving nutrition and physical activity and preventing obesity in the European Union. Report n° 10.EUR/10/EUDHP 1003693/8.1/10.
[14] Paffenbarger RS Jr, Hyde RT, Wing AL, et al. The association of changes in physical-activity level, and other lifestyle characteristics with mortality among men. N. Engl. J. Med. 1993; 328: 538-45.
[15] Chave SPW, Morris JN, Moss S, Semmence AM. Vigorous exercise in leisure time and the death rate: a study of male civil servants. J. Epidemiol Community Health 1978; 32: 239-43.
[16] Salonen JT, Puska P, Tuomilehto J. Physical activity and risk of myocardial infarction, cerebral stroke and death: a longitudinal study in Eastern Finland. Am. J. Epidemiol 1982; 115: S26-37.
[17] Blair SN, Kohl HW III, Paffenbarger RS Jr., et al. Physical fitness and all-cause mortality: a prospective study of healthy men and women. JAMA 1989; 262: 2395-401.
[18] Lindsted KD, Tonstad S, Kuzma JW. Self-report of physical activity and patterns of mortality in Seventh-Day Adventist men. J. Clin. Epidemiol 1991; 44: 355-64.
[19] Leone A. Cigarette smoking and health of the heart. J. Roy Soc Health 1995; 115:
354-5.
[20] International Cardiovascular Disease Statistics 2003. Dallas, Texas; American Heart Association, May 2003.
[21] Morris JN, Clayton DG, Everitt MG, et al. Exercise in leisure-time: coronary attack and death rates. Br. Heart J. 1990; 63: 325-34.
[22] Slattery ML, Jacobs DR Jr., Nichaman MZ. Leisure time physical activity and coronary heart disease death: the US Railroad Study. Circulation 1989; 79: 304-11.
[23] Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-6.
[24] Taddei S, Ghiadoni L, Virdis A, et al. Mechanisms of endothelial dysfunction: Clinical significance and preventive non-pharmacological therapeutic strategies. Curr. Pharm. Des. 2003; 9: 2385-2402.
[25] Maiorana A, O’Driscoll G, Cheetham C, et al. The effect of combined aerobic and resistance exercise training on vascular function in type 2 diabetes. J. Am. Coll Cardiol 2001; 38: 860-6.
[26] Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998; 98: 2709-15.
[27] DeSouza CA, Shapiro LF, Clevenger CM, et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation 2000; 102: 1351-7.
[28] Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
[29] Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, Packer L. Factors associated with oxidative stress in human populations. Am. J. Epidemiol 2002; 156: 274 – 85.
[30] Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol 2003; 91: 7A – 11A.
[31] Leone A. Oxidative metabolic stress and antioxidant supplementation. In: Passive Smoking and Cardiovascular Pathology. Mechanisms and Physiopathological Bases of Damage, 2nd Ed., Leone A ed., Cardiology Research and Clinical Development, Nova Biomedical, New York, USA, 2012; 131-2.
[32] May JM. How does ascorbic acid prevent endothelial dysfunction? Free Radic Biol Med. 2000; 28: 1421-9.
[33] Schectman G, Byrd JC, Gruchow HW. The influence of smoking on vitamin C status in adults. Am. J. Public Health 1989; 79: 158-62.
[34] Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl. J. Med 1993; 328: 1450-6.
[35] The Alpha-Tocopherol , Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl. J. Med. 1994; 330: 1029-35.
[36] Alarcon de la Lastra C, Barranco MD, Motilva V, Herrerias JM. Mediterranean diet and health: biological importance of olive oil. Curr. Pharm. Des. 2001; 7 (10): 933-50.
[37] Woo KS, Chook P, Lolin YI, et al. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J. Am. Coll. Cardiol. 1999; 34: 2002-6.
[38] Bellamy MF, McDowell IF, Ramsey MW, et al. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur. J. Clin. Invest 1999; 29: 659-62.
[39] Goode GK, Garcia S, Heagerty AM. Dietary supplementation with marine fish oil improves in vitro small artery endothelial function in hypercholesterolemic patients: a double-blind placebo-controlled study. Circulation 1997; 96: 2802-7.
[40] Duffy SJ, Keaney JF Jr., Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001; 104: 151-6.
[41] Flesch M, Schwarz A, Bohm M. Effects of red and white wine on endothelium-dependent vasorelaxation of rat aorta and human coronary arteries. Am. J. Physiol 1998; 275: H1183-90.
[42] Myers J, Prakash M, Froeliker V, et al. Exercise capacity and mortality among men referred for exercise testing. N Engl. J. Med 2002; 346: 793-801.
[43] Leone A. Cardiovascular damage from smoking: a fact or belief? Int. J. Cardiol 1993; 38: 113-7.
[44] US Public Health Service, Office of the Surgeon General. Physical Activity and Health: A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
[45] World Health Organization. The World Health Report 2002: Reducing risks, promoting healthy life. Geneva: WHO; 2002.
[46] Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97 (6): 596-601.
[47] Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999; 353 (9147): 89-92.
[48] Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97 (18): 1837-47.
[49] Landini L, Leone A. Smoking and hypertension: Effects on clinical, biochemical and pathological variables due to isolated or combined action on cardiovascular system. Curr. Pharm Des. 2011; 17: 2987-3001.
[50] Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular disease in the United States: Findings of the National Conference on Cardiovascular Disease Prevention. Circulation 2000; 102 (25): 3137-47.
[51] Williams GH. Quality of life and its impact on hypertensive patients. Am. J. Med. 1987; 82: 98-105.
[52] Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-23.
[53] Baroldi G, Radice F, Schmid G, Leone A. Morphology of acute myocardial infarction in relation to coronary thrombosis. Am. Heart J. 1974; 87 (1): 65-75.
[54] Cantin M, Leone A. Morphology of myocardial infarction. Methods Achiev Exp Pathol 1981; 10: 244-84.
[55] Kannel WB, Cupples LA, D’Agostino RB. Sudden death risk in overt coronary heart disease: the Framingham Study. Am. Heart J. 1987; 113: 799-804.
[56] Cobb LA, Werner JA. Predictors and Prevention of Sudden Cardiac Death. In Hurst “The Heart” Sixt Ed., Mc-Graw-Hill, New York, USA, 1986; 538-46.
[57] Kannel WB, Thomas HE Jr. Sudden coronary death: The Framingham Study. Ann NY Acad. Sci. 1982; 382: 3-21.
[58] Kannel WB, Schatzkin A. Sudden death: Lessons from subsets in population study. J. Am. Coll Cardiol. 1985; 5: B141-9.
[59] Albert CM, Manson JE, Cook NR, et al. Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians. Circulation 1999; 100: 944-50.
[60] Lampert R, Joska T, Burg MM, et al. Emotional and physical precipitants of ventricular arrhythmia. Circulation 2002; 106: 1800-5.
[61] Hallstrom AP, Cobb LA, Ray R. Smoking as a risk factor for recurrence of sudden cardiac arrest. N Engl. J. Med. 1986; 314: 271-5.
[62] Leone A, Bertanelli F, Mori L, et al. Ventricular arrhythmias by passive smoking in patients with preexisting myocardial infarction. J. Am. Coll Cardiol. 1992; 3: 256 (A).
[63] Baroldi G. Myocardial infarct and sudden coronary heart death in relation to coronary occlusion and collateral circulation. Am. Heart J. 1966; 71 (6): 826-36.
[64] Myerburg RJ, Kessler KM, Basset AL, Castellanos A. A biological approach to sudden cardiac death: structure, function and cause. Am. J. Cardiol 1989; 63: 1512-6.
[65] Willich SN, Maclure M, Mittleman M, et al. Sudden cardiac death. Support for a role of triggering in causation. Circulation 1993; 87: 1442-50.
[66] You S, Yarnell JWG, Sweetnam PM, Murray L. What level of physical activity protects against premature cardiovascular death? The Caerphilly Study. Heart 2003; 89: 502-6.
[67] Hamer M, Ingle L, Carrol S, Stamatakis E. Physical activity and cardiovascular mortality risk: possible protective mechanisms? Med Sci Sport Exerc 2012; 44 (1) 84-8.
[68] Nocon M, Hiemann T, Muller-Riemenschneider F, et al. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. Eur. J. Cardiovasc Prev Rehabil 2008; 15 (3): 239-46.
[69] Shiroma EJ, Lee IM. Physical activity and cardiovascular health. Lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 2010; 122: 743-52.
[70] Sofi F, Capalbo A, Cesari F, et al. Physical activity during leisure time and primary prevention of coronary heart disease: an updated meta-analysis of cohort studies. Eur. J. Cardiovasc. Prev Rehabil 2008; 15: 247-57.
[71] Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am. J. Epidemiol 1990; 132:612-28.
[72] Folsom AR, Arnett DK, Hutchinson RG, et al. Physical activity and incidence of coronary heart disease in middle-aged women and men. Med Sci Sport Exerc 1997: 29: 901-9.
[73] Sherman SE, D’Agostino RB, Silbershatz H, Kannel WB. Comparison of past versus recent physical activity in the prevention of premature death and coronary artery disease. Am. Heart J. 1999; 138: 900-7.
[74] Lee IM, Sesso HD, Paffembarger RS Jr., Physical activity and coronary heart disease risk in men: does the duration of exercise episodes predict risk? Circulation 2000; 102; 981-6.
[75] Lee IM, Rexrode KM, Cook NR, et al. Physical activity and coronary heart disease in women: is “no pain, no gain” passe? JAMA 2001; 285; 1447-54.
[76] Lissner L, Bengtsson C, Byorkelund C, Wedel H. Physical activity levels and changes in relation to longevity: a prospective study of Swedish women. Am. J. Epidemiol 1996; 143: 54-62.
[77] Talbot LA, Morrel CH, Metter EJ, Fleg JL. Comparison of cardiorespiratory fitness versus leisure time physical activity as predictors of coronary events in men aged 65 years. Am. J. Cardiol 2002; 89: 1187-92.
[78] Gregg EW, Gerzoff RB, Caspersen CJ, et al. Relationship of walking to mortality among US adults with diabetes. Arch. Intern Med. 2003; 163: 1440-7.
[79] Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. Public Health Rep 1985; 100:126-31.
[80] Leone A, Mori L, Bertanelli F, et al. Indoor passive smoking: its effect on cardiac performance. Int. J. Cardiol. 1991; 33: 247-51.

Chapter 5

[1] Leone A, Centaro E, Leone A. The control of arterial hypertension: Epidemiological and economic challenge. Curr. Hypertens Rev 2012; 8: 151-8.
[2] Inter-Society Commission for Heart Disease Resources. Atherosclerosis Study Group and Epidemiology Study Group: Primary prevention of the atherosclerotic diseases. Circulation 1970; 42: A55-95.
[3] Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: risk of cardiovascular disease and preventive measures. Curr. Pharm Des. 2003; 9: 2417-23.
[4] Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
[5] Landini L, Leone A. Smoking and hypertension: effects on clinical, biochemical and pathological variables due to isolated or combined action on cardiovascular system. Curr. Pharm Des. 2011; 17: 2987-3001.
[6] Leone A. Passive smoking exposure and cardiovascular health. In: Passive Smoking and Health Research, Jeorgensen NA ed, Nova Science Publishers, New York, USA, 2007; 65-94.
[7] Benjamin EJ, Smith SC Jr, Cooper RS, Hill MN, Luepker RV. Task Force # 1-magnitude of the prevention problem: Opportunities and challenges. 33rd Bethesda Conference. J. Am. Coll Cardiol 2002; 40: 588 – 603.
[8] Majno G. The Healing Hand. Cambridge, MA, Harward University Press, 1975: 43.
[9] Wilson PWF. Established risk factors and coronary artery disease: The Framingham Study. Am. J. Hypertens 1994; 7: S7-12.
[10] Fuster V, Pearson TA. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary heart disease events. J. Am. Coll Cardiol. 1996; 27: 957-1047.
[11] Keys A, Aravanis C, Blackburn H, et al. The probability of middle aged men developing coronary heart disease in five years. Circulation 1972; 45: 815-28.
[12] Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986; 256: 2823-8.
[13] Glantz SA, Parmley WW. Passive smoking and heart disease. Epidemiology, physiology, and biochemistry. Circulation 1991; 83: 1-12.
[14] Leone A. The economic costs for the control of cardiovascular risk: An overview. Curr. Pharm Des. 2013; 19 (13): 2447-53.
[15] Epstein A. Performance reports on quality: Prototypes, problems, and prospects. N Engl J. Med. 1995; 333: 57-61.
[16] The Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329: 977-86.
[17] Morris JN. Uses of epidemiology. Morris JN ed., 3rd ed, CAB Direct, Wallingford, UK, 1975; pp 318.
[18] Spratt JS. The primary and secondary prevention of cancer. J. Surg. Oncol 1981; 18 (3): 219-30.
[19] Dekker G, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia. Lancet 2001; 357: 209-15.
[20] Gofrit ON, Shemer J, Leibovici D, et al. Quaternary prevention: a new look at an old challenge. Isr. Med. Assoc J. 2000; 2 (7): 498-500.
[21] Gordon T, Kannel WB, McGee D, Dawber TR. Death and coronary attacks in men after giving up cigarette smoking. A report from the Framingham Study. Lancet 1974; 2: 1345-8.
[22] Tsevat J, Weinstein MC, Williams LW, et al. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991; 83: 1194-1201.
[23] Critchley J A, Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease. A systematic review. JAMA 2003, 290: 86-97.
[24] van Domburg RT, Meeter K, van Berkel DF, et al. Smoking cessation reduces mortality after coronary artery bypass surgery. A 20-year follow-up study. J. Am. Coll. Cardiol. 2000; 36: 878-83.
[25] Taylor P. What is campaigning? In: Tobacco and Health, K Slama ed, Plenum Press, New York, USA, 1995; pp 37-9.
[26] Novello AC. Campaigns for young people. In. Tobacco and Health, K Slama ed, Plenum Press, New York, USA, 1995; pp 41-5.
[27] Leone A, Lopez M, Picerno G. Role of smoking in determining coronary heart disease. Hypothesis on the possible mechanism of myocardial damage. Min Cardioang 1984; 32: 435-9.
[28] Sparrow D, Dawber TR, Colton T. The influence of cigarette smoking on prognosis after a first myocardial infarction. J. Chronic. Dis 1978; 31: 425-32.
[29] Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet 1975; 1: 415-20.
[30] Leone A. Cardiovascular damage from smoking: a fact or belief? Int. J. Cardiol 1993; 38: 113-7.
[31] Daly LE, Mulkay R, Graham JM, Hickey N. Long-term effect on mortality of stopping smoking after unstable angina and myocardial infarction. BMJ 1983; 287: 324-6.
[32] Vlietstra RE, Kronmal RA, Oberman A. Stopping smoking improves survival in patients with angiographically-proven coronary artery disease. Am. J. Cardiol 1982; 49: 984A.
[33] Meinert CL, Forman S, Jacobs DR, Stamler J. Cigarette smoking as a risk factor in men with a prior history of myocardial infarction. J. Chronic Dis 1979; 32: 415-25.
[34] Leone A. Number of cigarettes, reinfarction/death in continuing smokers. Il Cuore 1990; 7: 233-6.
[35] Hermanson B, Omenn GS, Kronmal RA, Gersh BJ. Beneficial six-year outcome of smoking cessation in older men and women with coronary heart disease. Results from the CASS registry. N Engl. J. Med. 1988; 319: 1365-9.
[36] Collins R, McMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and coronary heart disease. Br. Med. Bull. 1994; 50: 272-98.
[37] Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996; 275: 1571-6.
[38] Leone A, Landini L, Leone A. Epidemiology and costs of hypertension-related disorders. Curr. Pharm. Des 2011; 17 (28): 2955-72.
[39] American Society of Hypertension. Hypertension Guidelines 2011.
[40] Stamler J, Daviglus ML, Garside DB, et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000; 284: 311-8.
[41] Libby P, Aikawa M, Schonbeck U. Cholesterol and atherosclerosis. Biochim. Biophys Acta 2000; 1529: 299-309.
[42] Gillum RF, Mussolino ME, Madans JH. Diabetes mellitus, coronary heart disease incidence, and death from all causes in African American and European American women: THE NHANES I: epidemiologic follow-up study. J. Clin. Epidemiol 2000; 53: 511-8.
[43] The University Group Diabetes Program. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 (Suppl 2): 787-830.
[44] Manson JE, Willet WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl. J. Med 1995; 333: 677-85.
[45] Jousilahti P, Tuomilehto J, Vartiainen E, et al. Body weight, cardiovascular risk factors, and coronary mortality: 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996; 93: 1372-9.
[46] Resch KL, Ernst E, Matai A, Paulsen HF. Fibrinogen and viscosity as risk factors for subsequent cardiovascular events in stroke survivors. Ann Intern Med 1992; 117: 371-5.
[47] Kramsch DM, Aspen AJ, Abramowitz BM, et al. Reduction of coronary atherosclerosis by moderate conditioning exercise in monkeys on an atherogenic diet. N. Engl. J. Med. 1981; 305: 1483- 9.
[48] Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction: Combined experience of randomized trials. JAMA 1988; 260: 945-50.
[49] Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: A statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 3109-16.
[50] Tanasescu M, Leitzmann MF, Rimm EB, et al. Exercise type and intensity in relation to coronary heart disease in men. JAMA 2002; 288 (16): 1994-2000
[51] Haskell WL. Sedentary lifestyle as a risk factor for coronary heart disease. In: Pearson TA et al. eds, Primer in Preventive Cardiology. Dallas, USA, American Heart Association 1994; pp 173-87.
[52] Stamler J, Wentworth D, Neaton JD, for the MRFIT Cooperative Research Group. Is the relationship between serum cholesterol and risk of death from coronary heart disease continuous and graded? Findings on 356,222 primary screeners of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823 – 8.
[53] Cornfield J. Joint dependence of risk of coronary heart disease on serum cholesterol and systolic blood pressure: A discriminant function and analysis. Fed Proc 1962; 21 (Suppl II): 58 – 61.
[54] Gotto AM Jr. Interactions of the major risk factors for coronary heart disease. Am. J. Med 1986; 80 (Suppl 2A): 48 –55.
[55] Criqui MH, Barret-Connor E, Holdbrook MJ, et al. Clustering of cardiovascular disease risk factors. Preventive Medicine 1980; 9: 525 – 33.
[56] Carlson LA, Bottiger LE, Ahfeldt PE. Risk factors for myocardial infarction in the Stockholm Prospective Study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Medica Scandinavica 1979; 206: 351 – 60.
[57] Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary event: Final report of the Pooling Project. J. Chronic Dis 1978: 31: 201 – 306.
[58] Robertson TL, Kato H, Gordon T, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California. Coronary heart disease risk factors in Japan and Hawaii. Am. J. Cardiol 1977; 39: 244–9.
[59] Wilhelmsen L. Risk factors for disease according to population studies in Goteborg, Sweden. In: Medical Aspects of Mortality Statistics. Skandinavia International Symposia, Bostrom H and Ljungstedt N eds, Almquist and Wiksell International, Stockholm 1981; 73 – 88.
[60] Leone A. Passive Smoking and Cardiovascular Pathology. Mechanisms and Physiopathological Bases of Damage, 2nd ed. A Leone ed., Cardiology Research and Clinical Developments, Nova Biomedical, Nova Science Publishers, Inc., New York, USA, 2012.
[61] Williams PT, Thompson PD. Walking versus running for hypertension, cholesterol, and diabetes mellitus risk reduction. Arterioscler Thromb Vasc Biol. 2013; 33(5):1085-91.

Chapter 6

[1] Leone A. Cardiovascular damage from smoking: A fact or belief? Int. J. Cardiol 1993; 38: 113-7.
[2] Sherman CB. Health effects of cigarette smoking. Clin. Chest Med. 1991; 12 (4):
643-58.
[3] Leone A. The heart: A target organ for cigarette smoking. J. Smoking- Related Dis 1992; 3: 197-201.
[4] US Department of Health, Education, and Welfare: The health consequences of smoking: A report of the Surgeon General. Cardiovascular disease. Rockville, MD: US Department of Health and Human Services, Public Health Service Office of Smoking and Health. DHHS Publication NO (PHS) 84-50204, 1983.
[5] Leone A. Cigarette smoking and health of the heart. J. R. Soc. Health 1995; 115: 354-835.
[6] Flouris AD, Metsios GS, Jamurtas AZ, Koutedakis Y. Cardiorespiratory and immune response to physical activity following exposure to a typical smoking environment. Heart 2010; 96 (11): 860-4.
[7] McBride PE. The health consequences of smoking. Cardiovascular diseases. Med. Clin. North Am. 1992; 76: 333-53.
[8] Aronow WS. Effect of passive smoking on angina pectoris. N. Engl. J. Med. 1978; 299: 21-4.
[9] Sparrow D, Dawber TR, Colton T. The influence of cigarette smoking on prognosis after a first myocardial infarction. J. Chronic Dis. 1978; 31: 425-32.
[10] Leone A, Bertanelli F, Mori L, et al. Ventricular arrhythmias by passive smoke in patients with preexisting myocardial infarction. J. Am. Coll Cardiol. 1992; 3: 256 (A).
[11] Wilhelmsson C, Vedin JA, Elmfeldt D, et al. Smoking and myocardial infarction. Lancet 1975; 1: 415-20.
[12] Auerbach O, Carter HW, Garfinkel L, Hammond EC. Cigarette smoking and coronary heart disease, a macroscopic and microscopic study. Chest 19 76; 70: 697-705.
[13] Reid DD, Hamilton PJS, McCartney P, Rose G. Smoking and other risk factors in coronary heart disease in British civil servants. Lancet 1976; 11: 979-84.
[14] Glantz SA, Parmley WW. Passive smoking and heart disease. JAMA 1995; 273:
1047-53.
[15] Wells AJ. Passive smoking as a cause of heart disease. J. Am. Coll Cardiol 1994; 24: 546-54.
[16] Meinert CL, Forman S, Jacobs DR, Stamler J. Cigarette smoking as a risk factor in men with a prior history of myocardial infarction. J. Chronic Dis 1979; 32: 415-25.
[17] Glantz SA, Parmley WW. Passive smoking and heart disease: Epidemiology, physiology, and biochemistry. Circulation 1991; 83: 1-12.
[18] Baer L, Radichevich I. Cigarette smoking in hypertensive patients. Blood pressure and endocrine responses. Am. J. Med. 1985; 78: 564-8.
[19] Celermajer DS, Adams MR, Clarkson P, et al. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N. Engl. J. Med. 1996; 334: 150-4.
[20] Leone A, Lopez M. Oral contraception, ovarian disorders and tobacco in myocardial infarction of woman. Pathologica 1986; 78: 237-42.
[21] Pojola S, Siltanen P, Romo M. Five-year survival of 728 patients after myocardial infarction. Br. Heart J. 1980; 43: 176-83.
[22] Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: Risk of cardiovascular disease and preventive measures. Curr. Pharm Des 2003; 9: 2417-23.
[23] Byrd JC. Environmental tobacco smoke. Medical and legal issues. Med. Clin. North Am. 1992; 76: 377-97.
[24] Peto R, Lopez AD, Boreham J, et al. Mortality from smoking in developed countries: 1950 - 2000. Oxford: Oxford University Press 1994.
[25] Wald NJ, Hackshaw AK. Cigarette smoking: An epidemiological overview. Br. Med. Bull 1996; 52: 3-11.
[26] Leone A, Bertanelli F, Mori L, et al. Features of ischaemic cardiac pathology resulting from cigarette smoking. J. Smoking Related Dis. 1994; 5: 109-14.
[27] Health or Smoking. Follow-up Report of the Royal College of Physicians. Pitman Publishing: London 1983.
[28] Astrup P. The arterial wall in atherogenesis. In: Cavallero Ed. Atherogenesis. Padua, Italy, Piccin Medical Books 1965: 77-92.
[29] Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr. Pharm. Des. 2005; 11: 2199-208.
[30] Leone A, Landini L Jr, Biadi O, Balbarini A. Smoking and cardiovascular system: Cellular features of the damage. Curr. Pharm Des. 2008; 14: 1771-7.
[31] Doyle JT, Dawber TR, Kannel WB. The relationship of cigarette smoking to coronary heart disease: The second report of the combined experience of the Albany NY, and Framingham, Mass, studies. JAMA 1964; 190: 886-90.
[32] Strong JP, Richards ML, McGill HC Jr. On the association of cigarette smoking with coronary and aortic atherosclerosis. J. Atheroscler Res. 1969; 10: 303-17.
[33] Eliot RS, Baroldi G, Leone A. Necropsy studies in myocardial infarction with minimal or no coronary luminal reduction due to atherosclerosis. Circulation 1974; 49: 1127-31.
[34] Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking associated hemodynamic and metabolic events. N. Engl. J. Med. 1976; 295: 573-7.
[35] Grassi G, Seravalle G, Calhoun DA, et al. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation 1994; 90: 248-53.
[36] Groppelli A, Giorgi DM, Omboni S, et al. Persistent blood pressure increase induced by heavy smoking. J. Hypertens 1992; 10: 495-9.
[37] Schievelbein H, Richter F. The influence of passive smoking in the cardiovascular system. Prev. Med. 1984; 13: 626-44.
[38] Pope CA 3rd, Eatough DJ, Gold DR, et al. Acute exposure to environmental tobacco smoke and heart rate variability. Environ Health Perspect 2001; 109: 711-6.
[39] Leone A. Five markers capable to identify passive smoking exposure associated with endothelial dysfunction in healthy individuals. Curr. Hypertens Rev 2008; 4: 183-9.
[40] Mahmud A, Feely G. Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension 2003; 41:183-7.
[41] Masala G, Bendinelli B, Versari D, et al. Anthropometric and dietary determinants of blood pressure in over 7000 Mediterranean women: The European Prospective Investigation into Cancer and Nutrition-Florence cohort. J. Hypertens 2008; 26:
2112-20.
[42] Ross RK, Paganini-Hill A, Mack TM, et al. Menopausal oestrogen therapy and protection from death from ischaemic heart disease. Lancet 1981; 1: 858-60.
[43] Hurn PD, Brass ML. Estrogen and stroke: A balanced analysis. Stroke 2003; 34:
338-41.
[44] Higashi Y, Sanada M, Sasaki S, et al. Effect of estrogen replacement therapy on endothelial function in peripheral resistance arteries in normotensive and hypertensive postmenopausal women. Hypertension 2001; 37: 651-7.
[45] Primatesta P, Falaschetti E, Gupta S, et al. Association between smoking and blood pressure: Evidence from the health survey for England. Hypertension 2001; 37: 187-93.
[46] Minami J, Ishimitsu T, Matsuoka H. Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension 1999; 33: 586-90.
[47] Lee DH, Ha MH, Kim JR, Jacobs DR, Jr. Effects of smoking cessation on changes in blood pressure and incidence of hypertension: A 4-year follow-up study. Hypertension 2001; 37:194-8.
[48] Bonita R, Duncan J, Truelsen T, et al. Passive smoking as well as active smoking increase the risk of acute stroke. Tob Control 1999; 8: 156-60.
[49] US Department of Health and Human Services. The health consequences of involuntary smoking. A Report of the General Surgeons; Rockville, Md. Office on Smoking and Health DHHS Publication 1981; n° (CDC) 87-8398.
[50] Kritz H, Schmid P, Sinzinger H. Passive smoking and cardiovascular risk. Arch. Intern. Med. 1995;155: 1942 – 8.
[51] World Health Organization. The World Health Report 2002: Reducing risks, promoting healthy life. Geneva 2002: WHO.
[52] Doll R, Peto R. Mortality in relation to smoking: 20 years’ observations on male British doctors. BMJ 1976; 25 (2): 1525 – 36.
[53] Giovino GA. Epidemiology of the tobacco use in the United States. Oncogene 2002; 21: 7326 – 39.
[54] Steenland K. Passive smoking and the risk of the heart disease. JAMA 1992; 267:
94 – 9.
[55] Lee PN, Chamberlain J, Alderson MR. Relationship of passive smoking to risk of lung cancer and other smoking-associated diseases. Br. J Cancer 1986; 54: 97 – 105.
[56] Hole DJ, Gillis CR, Chopra C, Hawthorne WM. Passive smoking and cardiorespiratory health in a general population in the west of Scotland. BMJ 1989; 299: 423 – 7.
[57] Kawachi I, Colditz GA, Speizer FE, et al. A prospective study of passive smoking and coronary heart disease. Circulation 1997; 95: 2374 – 9.
[58] Helsing K, Sandler D, Comstock G, Chee E. Heart disease mortality in nonsmokers living with smokers. Am. J. Epidemiol. 1988; 127: 915 – 22.
[59] Steenland K, Thun M, Lally C, Heath C Jr. Environmental tobacco smoke and coronary heart disease in the American Cancer Society CPS-II cohort. Circulation 1996; 94:
622 – 8.
[60] Sandler DP, Comstock JW, Helsing KJ, Shore DL. Death from all causes in non-smokers who lived with smokers. Am. J. Public Health. 1989; 79: 163 - 7.
[61] Svendsen KH, Kuller LH, Martin MJ, Ockene JK. Effects of passive smoking in the multiple risk factor intervention trials. Am. J. Epidemiol. 1987; 126: 783 – 95.
[62] Garland C, Barret-Connor E, Suarez L, et al. Effects of passive smoking on ischemic heart disease mortality of nonsmokers. Am. J. Epidemiol. 1985; 121: 645 – 50.
[63] He Y, Li L, Wang Z, et al. Women’s passive smoking and coronary heart disease. Chin. J. Prev. Med. 1989; 23: 19 – 22.
[64] Humble C, Croft J, Gerber A, et al. Passive smoking and 20-year cardiovascular disease mortality among nonsmoking wives, Evans County, Georgia. Am. J. Public Health. 1990; 80: 599 – 601.
[65] Muscat JE, Wynder EL. Exposure to environmental tobacco smoke and the risk of heart attack. Int. J. Epidemiol. 1995; 24: 715 – 9.
[66] La Vecchia C, D’Avanzo B, Franzosi MG, Tognoni G. Passive smoking and the risk of acute myocardial infarction. Lancet 1993; 341: 505 – 6.
[67] He Y, Lam TH, Li LS, et al. Passive smoking at work as a risk factor for coronary heart disease in Chinese women who have never smoked. BMJ 1994; 308: 380 – 4.
[68] Layard MW. Ischemic heart disease and spousal smoking in the National Mortality Followback Survey. Regular Toxicol. Pharmacol. 1995; 21: 180 – 3.
[69] He Y, Lam TH, Li LS, et al. The number of stenotic coronary arteries and passive smoking exposure from husband in lifelong non-smoking women in Xi’an, China. Atherosclerosis 1996; 127 (2): 229 – 38.
[70] Hirayama T. Passive smoking (letter). NZ. Med. J. 1990; 103: 54.
[71] LeVois ME, Layard MW. Publication bias in the environmental tobacco smoke/coronary heart disease epidemiologic literature. Regular Toxicol. Pharmacol. 1995; 21: 184 – 91.
[72] Howard G, Burke GL, Szklo M, et al. Active and passive smoking are associated with increased carotid wall thickness. Arch. Intern. Med. 1994; 154: 1277 – 82.
[73] Leone A. Passive smoking exposure and cardiovascular response to the damage. In: Handbook of Cardiovascular Research, chapter III, Braatas J and Nansteit V eds, Nova Science Publishers, New York, USA, 2009; pp: 81-111.
[74] Howard G, Wagenknecht LE, Burke GL, et al. Cigarette smoking and progression of atherosclerosis; The atherosclerosis risk in communities (ARIC ) study. JAMA 1998; 279: 119 – 24.
[75] Werner RM, Pearson TA. What is so passive about passive smoking? Secondhand smoke as a cause of atherosclerotic disease. JAMA 1998; 279: 157 – 8.
[76] Salonen JT, Salonen R. Ultrasonography assessed carotid morphology and risk of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 1991; 11: 1245 – 9.
[77] Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432 – 7.
[78] Mikhailidis DP, Barradas MA, Nystrom ML, Jeremy JY. Cigarette smoking increases with blood cells aggregation in whole blood. J. Roy. Soc. Med. 1993; 86 (11 ): 680 – 1.
[79] Stefanidis C, Vlachopoulos C, Tsiamis E. Unfavorable effects of passive smoking in aortic function in men. Ann. Intern. Med. 1998; 128: 426 – 34.
[80] Neufeld EJ, Mietus-Snyder M, Beiser AS, et al. Passive cigarette smoking and reduced HDL cholesterol levels in children with high risk lipid profiles. 1997; 96: 1403 – 7.
[81] Zhu BQ, Sun YP, Sievers RE, et al. Passive smoking increases experimental atherosclerosis in cholesterol fed rabbits. J. Am. Coll. Cardiol. 1993; 21: 225 – 32.
[82] Penn A. Butadiene, a vapor phase component of environmental tobacco smoke, accelerates atherosclerotic plaque development. Circulation 1996; 93: 552P.
[83] Sumida H, Watanabe H, Kugiyama K, et al. Does passive smoking impair endothelium-dependent coronary artery dilation in women? J. Am. Coll. Cardiol. 1998; 31: 811 – 5.
[84] Otsuka R, Watanabe H, Hirata K, et al. Acute effects of passive smoking on the coronary circulation in healthy young adults. JAMA 2001; 286: 436 – 41.
[85] Celermajer DS, Sorensen KE, Gooch VM, et al. Noninvasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340:
1111 – 5.
[86] Davis J, Shelton L, Watanabe I, Arnold J. Passive smoking affects endothelium and platelets. Arch. Intern. Med. 1989; 149; 386 – 9.
[87] Deedwania PC. Endothelium: a new target for cardiovascular therapeutics. J. Am. Coll. Cardiol. 2000; 35: 67 – 70.
[88] Kugiyama K, Yasue H, Okomura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation 1996; 94: 266 – 72.
[89] Penn A, Chen LC, Snyder CA. Inhalation of steady-state sidestream smoke from cigarettes promotes atherosclerotic plaque development. Circulation 1994; 90:
1363 – 7.
[90] Giannini D, Leone A, Di Bisceglie D, et al. The effects of acute passive smoke exposure on endothelium-dependent brachial artery dilatation in healthy individuals. Angiology 2007; 58: 211-7.
[91] Sinzinger H, Kefalides A. Passive smoking severely decreases platelet sensitivity to antiaggregatory prostaglandins. Lancet 1982; 2: 392 – 3.
[92] Burghuber O, Punzengruber C, Sinzinger H, et al. Platelet sensitivity to prostacyclin in smokers and non-smokers. Chest 1986; 90: 34 – 8.
[93] Taylor AE, Johnson DC, Kazemi H. Environmental tobacco smoke and cardiovascular disease: a position paper from the Council on Cardiopulmonary and Critical Care , American Heart Association. Circulation 1992; 86: 699 – 702.
[94] Raitakari OT, Adams MR, McCredie RJ, et al. Passive-smoke related arterial endothelial dysfunction is potentially reversible in healthy young adults. Ann. Intern. Med. 1999; 130: 578 – 81.
[95] Leone A, Giannini D, Bellotto C, Balbarini A. Passive smoking and coronary heart disease. Curr Vasc Pharmacol 2004; 2: 175 – 82.
[96] Asahara T, Murohara T, Sullivan A, et al. Isolation of putative endothelial progenitor cells for angiogenesis. Science 1997; 275: 964-7.
[97] Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function and cardiovascular risk. N Engl. J. Med 2003; 348: 593-600.
[98] Walter DH, Ritting K, Bahlmann FH, et al. Statin therapy accelerates reendothelization: A novel effect involving mobilization and incorporation of bone- marrow derived endothelial progenitor cells. Circulation 2002; 105: 3017-24.
[99] Murohara T, Ikeda H, Duan J, et al. Transplanted cord blood-derived endothelial progenitor cells augment postnatal neovascularisation. J. Clin. Invest 2000; 105: 1527-36.
[100] Wang XX, Zhu JH, Chen JZ, Shang YP. Effects of nicotine on the number and activity of circulating endothelial progenitor cells. J. Clin. Pharmacol 2004; 44. 881-9.
[101] Armani C, Landini L Jr, Leone A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr. Pharm. Des 2009; 15: 1038-53.
[102] Armani C, Landini L, Leone A. Interactive effect of cigarette smoking and gene variants for predisposing to cardiovascular disease. Curr. Pharm Des 2010; 23: 2531-8.
[103] Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362: 847-52.
[104] He Y, Lam TH, Jiang B, et al. Combined effects of tobacco smoke exposure and metabolic syndrome on cardiovascular risk in older residents of China. J. Am. Coll Cardiol 2009; 53: 363-7.
[105] Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: A population-based study. Risk factor and life expectancy research group. Am. J. Epidemiol 1998; 148: 958-66.
[106] Lakka HM, Laaksonen DE, Lakka TA. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
[107] Taylor BV, Oudit GY, Kalman PG, Liu P. Clinical and pathophysiological effects of active and passive smoking on the cardiovascular system. Can. J. Cardiol 1998; 14 (9): 1129-39.
[108] Folts JD, Bonebrake FC. The effects of cigarette smoke and nicotine on platelet thrombus formation in stenosed dog coronary arteries: Inhibition with phentolamine. Circulation 1982; 65: 465-70.
[109] Leone A .Interactive effect of combined exposure to active and passive smoking on cardiovascular system. Rec Pat Cardiovasc Drug Discov 2011; 6: 61-9.
[110] Kice JL, Marvell EN. Modern Principles of Organic Chemistry. An Introduction. 3rd ed, The Macmillan Company, New York, USA, 1967.
[111] Armitage AK, Turner DM. Absorption of nicotine in cigarette and cigar smoke through the oral mucosa. Nature 1970; 226: 1231 – 2.
[112] Armitage AK, Dollery CT, George CF, Houseman TH, Lewis PJ, Turner DM. Absorption and metabolism of nicotine from cigarettes. BMJ 1975; 4: 313 – 6.
[113] Ball K, Turner R. Smoking and the heart: the basis for action. Lancet 1974; 2: 822 – 6.
[114] Benowitz NL, Jacob P III, Jones RT, Rosemberg J. Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J. Pharmacol. Exp. Ther1982; 221: 368 – 72.
[115] Castro de Souza EM, Silva MRE Jr. The release of vasopressin by nicotine: Further studies on its site of action. J. Physiol 1977; 265: 297 – 311.
[116] Cohen AJ, Roe FJC. Monograph on the Pharmacology and Toxicology of Nicotine. Tobacco Advisory Council Occasional Paper 4, 1981; London, 45.
[117] 118. Turner DM, Armitage AK, Briant RH, Dollery CT. Metabolism of nicotine by the isolated perfused dog lung. Xenobiotica 1975; 5: 539 – 51.
[118] Benowitz NL. Cotinine as a biomarker of environmental tobacco smoke exposure. Epidemiol. Rev. 1996; 18: 188 – 204.
[119] Leone A, Mori L, Bertanelli F, et al. Indoor passive smoking: Its effects on cardiac performance. Int. J. Cardiol 1991; 8: 247-52.
[120] Adams JD, Erickson HH, Stone HL. Myocardial metabolism during exposure carbon monoxide in the conscious dog. J. appl. Physiol. 1973; 34: 238 – 42.
[121] Horwath SM, Raven PB, Dahms TE, Gray DJ. Maximal aerobic capacity at different levels of carboxyhemoglobin. J. appl. Physiol 1975; 38: 300 – 3.
[122] Lewey FH, Drabkin DD. Experimental chronic carbon monoxide poisoning of dogs. Am. J. Med. Sci. 1944; 208: 502 – 11.
[123] Ehrich WE, Bellet S, Lewey FH. Cardiac changes from CO poisoning. Am. J. Med Sci 1944; 208: 512 – 23.
[124] Musselman NP, Groff WA, Yevich PP, et al. Continuous exposure of laboratory animals to low concentration of carbon monoxide. Aerosp. Med. 1959; 30: 524 – 9.
[125] Anderson RF, Allensworth DC, DeGroot WJ. Myocardial toxicity from carbon monoxide poisoning. Ann. Int. Med. 1967; 11:72 – 82.
[126] Leone A. Biochemical markers of passive smoking. In: Passive Smoking and Cardiovascular Pathology. Mechanisms and Physiopathological Bases of Damage, A. Leone ed, 2nd ed, Cardiology Research and Clinical Developments, Nova Biomedical, Nova Science Publishers, Inc., New York, USA, 2012; pp: 23-41.
[127] Norback D, Edling C. Environmental, occupational, and personal factors related to the prevalence of sick building syndrome in the general population. Br. J. Ind. Med. 1991; 48: 451 – 62.
[128] McKinley JB. The promotion of health through planned sociopolitical change: Challenges for research and policy. Soc. Sci. Med. 1993; 36: 109 – 17.
[129] Brownson RC, Matson Koffman D, et al. Environmental and policy interventions to control tobacco use and prevent cardiovascular disease. Health Education Quarterly 1995; 22: 478 – 98.
[130] Bernaards CM, Twisk JW, Van Mechelen W, et al. A longitudinal study on smoking in relationship to fitness and heart response. Med. Sci. Sports Exerc 2003; 35 (5): 793-800.
[131] Conway TL, Cronan TA. Smoking, exercise, and physical fitness. Prev. Med. 1992; 21 (6): 723-34.

Chapter 7

[1] Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
[2] Salvetti A, Versari D. Control of blood pressure in the Community: An unsolved problem. Curr. Pharm. Des 2003; 9: 2375-84.
[3] Collins R, Peto R, McMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
[4] Pearson TA. Cardiovascular disease in developing countries: Myths, realities, and opportunities. Cardiovasc. Drug Ther 1999; 13 (2): 95-104.
[5] Leone A, Landini L, Leone A. Epidemiology and costs of hypertension-related disorders. Curr. Pharm. Des 2011; 17: 2955-72.
[6] International Cardiovascular Disease Statistics. 2003. Dallas, Texas; American Heart Association, May 2003.
[7] Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97 (6): 596-601.
[8] Barker DJP. Fetal origins of coronary heart disease. BMJ 1995; 311: 171-4.
[9] Armani C, Landini L Jr, Leone A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr. Pharm. Des. 2009; 15: 1038-53.
[10] Armani C, Landini L, Leone A. Interactive effect of cigarette smoking and gene variants for predisposing to cardiovascular disease. Curr. Pharm. Des. 2010; 23:
2531-8.
[11] Yusuf S, Reddy S,Ounpuu S, Anand S. Global burden of cardiovascular disease, Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104: 2746-53.
[12] Goldman L, Cook EF. The decline in ischemic heart disease mortality rate: An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann. Intern. Med. 1984; 101: 825-36.
[13] Hunink MG, Goldman L, Tosteson AL, et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. JAMA 1997; 277: 535-42.
[14] Cooper R, Cutler J, Desvigne-Nickens P, et al. Disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the National Conference on Cardiovascular Disease Prevention. Circulation 2000; 102: 3137-47.
[15] Leone A. Statistics for understanding damage. In: Passive Smoking and Cardiovascular Pathology. Mechanisms and Physiopatholgical Basis of Damage, A. Leone ed, Nova Science Publishers, Inc., New York, USA 2007; pp: 119-31.
[16] Hachinski V. Stroke prevention. In: 23rd Congress of the International Society of Internal Medicine, Aquino AV, Piedad FF, Sulit YQM eds, Monduzzi Ed, International Proceedings Division, Bologna, Italy, 1996; pp.257-61.
[17] Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med. 2001; 345: 1291-7.
[18] Lloyd-Jones DM, Evans JC, Larson MG, Levy D. Treatment and control of hypertension in the community: A prospective analysis. Hypertension 2002; 40: 640-6.
[19] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: I. Results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 1967; 202; 1028-34.
[20] Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213: 1143-52.
[21] ALLHAT. Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
[22] Standridge JB. A family physician questions the conclusions from ALLHAT. Am. J. Hypertens 2004; 17: 361-5.
[23] Leone A. The Economic Costs for the Control of Cardiovascular Risk: An Overview. Curr. Pharm. Des. 2013; 2447-53.
[24] The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342: 145-53.
[25] Wing LMH, Reid CM, Ryan P, et al., for the Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 2003; 348: 583-92.
[26] Nadar S, Lim HS, Lip GY. Implications of the LIFE trial. Exp. Opin. Investig. Drugs 2003; 12 (5): 871-7.
[27] Black HR, Elliot WS, Neaton JD, et al., for the CONVINCE Research Group. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 2001; 37: 12-8.
[28] Beta Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 1982; 247: 1707-14.
[29] Jones RJ. β-blockade and recurrent myocardial infarction. JAMA 1982; 247: 2141-2.
[30] Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl. J. Med. 1992;327: 669-77.
[31] Doughty RN, Whalley GA, Walsh HA, et al., on behalf the CAPRICORN Echo Substudy Investigators. Effect of carvedilol on left ventricular remodelling after acute myocardial infarction. Circulation 2004; 109: 201-6.
[32] Kannel WB, Abbot RD. Incidence and prognosis of unrecognized myocardial infarction. N. Engl. J. Med. 1984; 311: 1144-7.
[33] Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: Risk of cardiovascular disease and preventive measures. Curr. Pharm. Des. 2003; 29: 2417-23.
[34] Julius S. Blood pressure lowering only or more? Has the Jury reached its verdict? Am. J. Cardiol. 2007; 100: J32-J7.
[35] Bahiru E, Kloner RA. A comparative literature review exploring hypertension drug that lower target organ damage above and beyond reducing blood pressure based on research studies between 1992-2006. Curr. Hypertens. Rev. 2008; 4: 167-76.
[36] Centaro E, Leone A. Risk of cardiovascular complications in hypertensive smokers: Metanalysis of small-case reports. Curr. Topics Pharmacol. 2012; 16: 25-30.
[37] Leone A. Coronary vascular endothelium. In: Coronary Circulation in Nonsmokers and Smokkers, A Leone ed, Nova Biomedical Books, Nova Science Publishers, Inc., New York, USA 2008; pp: 61-77.
[38] Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990; 323: 27-36.
[39] Fishman AP. Endothelium: a distributed organ of diverse capabilities. Ann. NY Acad. Sci. 1982; 401: 1-8.
[40] Cines DP, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-61.
[41] Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88: 2510-6.
[42] Desideri GB, Ferri C. Endothelial activation. Sliding door to atherosclerosis. Curr. Pharm. Des. 2005; 11: 2163-75.
[43] Taddei S, Ghiadoni L, Virdis A, et al. Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies. Curr. Pharm. Des. 2003; 9: 2385-402.
[44] Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
[45] Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium- dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. 1990; 323: 22-7.
[46] Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995; 91: 1981-7.
[47] Payne RA, Wilkinson IB, Webb DJ. Arterial stiffness and Hypertension. Emerging concepts. Hypertension 2010; 55:9-14.
[48] Stefanidis C, Vlachopoulos C, Tsiamis E. Unfavourable effects of passive smoking in aortic function in men. Ann. Intern. Med. 1998;128: 426-34.
[49] Greenwald SE. Ageing of the conduit arteries. J. Pathol. 2007; 211: 157-72.
[50] Leone A, Giannini D, Bellotto C, Balbarini A. Passive smoking and coronary heart disease. Current Vascular Pharmacology 2004; 2: 175-82.
[51] Wallace SM, Yasmin, Mc Eniery CM, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 2007; 50: 228-33.
[52] Schnabel R, Larson MG, Dupuis J, et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008; 51: 1651-7.
[53] Schumacher W, Cockcroft J, Timpson NJ, et al. Association between C-reactive protein genotype, circulating levels, and aortic pulse wave velocity. Hypertension 2009; 53: 150-7.
[54] Lip GYH, Blann AD. Does hypertension confer a prothromboticstate? Virchow’s triad revisited. Circulation 2000; 101: 218-20.
[55] Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr. Pharm. Des. 2005; 11: 2199-2208.
[56] Dockrell ME, Walker BR, Noon JP, et al. Platelet aggregation in young men with contrasting predisposition to high blood pressure. Am. J. Hypertens. 1999; 12: 115-9.
[57] Poole JFC, French JE. Thrombosis. J. Ather. Res. 1961; 1: 251-82.
[58] Preston RA, Jy W, Jiminez JJ, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41: 211-7.
[59] Vlachakis ND, Aledort L. Platelet aggregation in relationship to plasma catecholamines in patients with hypertension. Atherosclerosis1979; 32: 451-60.
[60] Varani K, Gessi S, Caiazza A, et al. Platelet alpha2-adrenoreceptor alterations in patients with essential hypertension. Br. J. Clin. Pharmacol. 1999; 47: 167-72.
[61] Blann AD, Nadar S, Lip GYH. Pharmacological modulation of platelet function in hypertension. Hypertension 2003; 42: 1-7.
[62] Haller H, Ludersdorf M, Lenz T, et al. Changes in sensitivity to angiotensin II in platelets. J. Cardiovasc. Pharmacol. 1987; 10(Suppl 10): S44-S7.
[63] Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev. 1978; 30: 293-331.
[64] Vargaftig BB, Chara M, Benveniste J. Present concepts on the mechanisms of platelet aggregation. Biochem. Pharmacol. 1981; 30:263-71.
[65] Hanahan DJ, Demopoulos CA, Liehr J, Pinckard RN. Identification of platelet activating factor isolated from rabbit basophils as acetylglyceril ether phosphorylcholine. J. Biol. Chem. 1980; 255: 5514-6.
[66] Winther K, Gleerup G, Hedner T. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence? J. Cardiovasc. Pharmacol. 1992; 19 (Suppl 3): S21-S4.
[67] Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers. J. Cardiovasc. Pharmacol. 1991; 18 (Suppl 9): S41-S4.
[68] Riondino S, Pignatelli P, Pulcinelli FM, et al. Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. J. Am. Geriatr. Soc. 1999; 47: 943-7.
[69] Torsellini A, Becucci A, Citi S, et al. Effects of pressure excursions on human platelet: in vitro studies on beta-thromboglobulin (beta-TG) and platelet factor 4 (PF-4) release and on platelet sensitivity to ADP-aggregation. Haematologica 1982; 67: 860-6.
[70] Howell WH. Theories of blood coagulation. Physiol. Rev. 1935: 15: 435-70.
[71] Tarazi RC, Frohlich ED, Dustan HP, et al. Hypertension and high hematocrit: another clue to renal arterial disease. Am. J. Cardiol. 1966; 18: 855-8.
[72] Sechi LA, Zingaro L, Catena C, et al. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension 2000: 36: 978-85.
[73] Kiwanuka E, Coracina A, Vettore M, et al. Fibrinogen kinetics and protein turnover in hypertension: Effects of insulin. Nutr. Metab. Cardiovasc. Dis. 2009; 19: 789-96.
[74] Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N. Engl. J. Med. 1997; 336: 1276-82.
[75] Burke AP, Farb A, Malcom GT, et al. Effect of risk factors on the mechanism of acute thrombosis and sudden coronary death in women. Circulation 1998; 97: 2110-6.
[76] Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid regulating therapy on haemostatic parameters. Curr. Pharm. Des. 2003; 9: 2425-43.
[77] Harrison CV, Wood P. Hypertensive and ischaemic heart disease: a comparative clinical and pathological study. Br. Heart J. 1949; 11: 205-9.
[78] Janeway T. A clinical study of hypertensive cardiovascular disease. Arch. Intern. Med. 1913; 12: 755-98.
[79] Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham Study. Ann. Intern. Med. 1979; 90: 85-91.
[80] Gordon T, Kannel WB, Castelli WP, Dawber TR. Lipoproteins, cardiovascular disease and death. The Framingham Study. Arch. Intern. Med. 1981; 141: 1128-31.
[81] Griffin JH, Fernandez JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001; 86: 386-94.
[82] Schachter M. The pathogenesis of atherosclerosis. Int. J. Cardiol. 1997; 62 (Suppl 20): S3-S7.
[83] Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am. J. Cardiol. 1998; 82: Q13-Q21.
[84] Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19: A31-A35.
[85] Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 2003; 91: A7-A11.
[86] Graziano JM, Sesso HD, Breslow JL, et al. Relation between systemic hypertension and blood lipids on the risk of myocardial infarction. Am. J. Cardiol. 1999; 84: 768-73.
[87] Fadl YY, Zareba W, Moss AJ, et al. History of hypertension and enhanced thrombogenic activity in postinfarction patients. Hypertension 2003; 41: 943-9.
[88] Kendall DM, Sobel BE, Coulston AM, et al. The insulin resistance syndrome and coronary artery disease. Coron. Art Dis. 2003; 14: 335-48.
[89] Reaven GM. The insulin resistance syndrome: Definition and dietary approaches to treatment. Ann. Rev. Nutr. 2005; 25: 391-406.
[90] Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-18.
[91] Kannel WB. Mild hypertension as a cardiovascular risk factor. Compr. Ther. 1981; 7: 7-14.
[92] Oster JR, Materson BJ, Epstein M. Diabetes mellitus and hypertension. Cardiovasc. Risk Factors 1990; l: 25-46.
[93] Sowers JR, Zemel MB. Clinical implications of hypertension in the diabetic patient: A Review. Am. J. Hypertens. 1990; 3: 415-24.
[94] Fuller JH. Epidemiology of hypertension associated with diabetes mellitus. Hypertension 1985; 2: 113-7.
[95] Stamler J, Rhomberg P, Schoenberg JA, et al. Multivariate analysis of the relationship of seven variables to blood pressure: Findings of the Chicago Heart Association Detection Project in Industry, 1967-1972. J. Chron. Dis. 1975; 28: 527-48.
[96] Mogensen CE. Diabetes and hypertension. Lancet 1979; 1: 388-9.
[97] Sowers JR: Hypertension in the elderly. Am. J. Med. 1987; 82 (Suppl lB): l-8.
[98] Harris MI, Hadden WC, Knowier WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in the US population aged 20-74 years. Diabetes 1987; 6: 523-34.
[99] Bild D, Teutsch SM. The control of hypertension in persons with diabetes: A public health approach. Public Health Rep. 1987; 102: 522-9.
[100] Leone A. Glucose metabolism and insulin resistance. In: Passive Smoking and Cardiovascular Pathology. Mechanisms and Physiopathological Bases of Damage, A Leone ed., Cardiology Research and Clinical Development, Nova Biomedical, Nova Science Publishers, Inc., New York, USA, 2012; pp: 130-1.
[101] Pan WH, Cedres LB, Liu K, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and woman. Am. J. Epidemiol. 1986; 123: 504-16.
[102] Barrett-Connor E, Wingard DL. Sex differential in ischemic heart disease mortality in diabetics: A prospective population-based study. Am J Epidemiol 1983; 118: 489-96.
[103] Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: An epidemiologic view. Diabetes/Metabolism Rev 1987; 3: 463-524.
[104] Oakley WG, Pyke DA, Tattersall RB, Watkins PJ. Long-term diabetes: A clinical study of 92 patients after 40 years. Q. J. Med. 1974; 43: 145-56.
[105] Borch-Johnson K, Nissen RN, Nerup J. Blood pressure after 40 years of insulin-dependent diabetes. Nephron 1985; 4: 11-2.
[106] Feskens EJ, Kromhout D. Cardiovascular risk factors and the 25- year incidence of diabetes mellitus in middle-aged men: the Zutphen Study. Am. J. Epidemiol. 1989; 130: 1101-8.
[107] Anderson EA, Mark AL. Cardiovascular and sympathetic actions of insulin: the insulin hypothesis of hypertension revised. Cardiovasc. Risk Factors 1993; 3: 159-63.
[108] Garrison RJ, Kannel WB, Stokes J III, Castelli WB. Incidence and precursors of hypertension in young adults: the Framingham offspring study. Prev. Med. 1987; 16: 235-51.
[109] Rahmouni K, Correia MLG, Haynes WG, Mark AL. Obesity-associated hypertension. New Insights into mechanisms. Hypertension 2005; 45. 9-14.
[110] Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003; 41: 625–33.
[111] Sironi AM, Gastaldelli A, Mari A, et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004; 44: 127-33.
[112] Kannel WB, Sorlie P. Hypertension in Framingham. In: O Paul ed, Epidemiology and control of hypertension. Symposia Specialists, Miami 1975; 553-92.
[113] Kissebah AH, Vydelingum N, Murray R, et al. Relation of body fat distribution to metabolic complications of obesity. J. Clin. Endocrinol. Metab. 1982; 54: 254-60.
[114] Wilson PW, McGee DL, Kannel WB. Obesity, VLDL and glucose tolerance over 14 years: the Framingham study. Am. J. Epidemiol. 1981; 114: 697-704.
[115] Bush DE, Bulkley BH. Management of patients with hypertension and angina pectoris. Am. J. Med. 1984; 77: 28-34.
[116] Roberts WC, Buja LM. The frequency and significance of coronary arterial thrombi and other observations in fatal acute myocardial infarction. A study of 107 necropsy patients. Am. J. Med. 1972; 52: 425-43.
[117] Roberts WC, Jones AA. Quantitation of coronary artery narrowing at necropsy in acute myocardial infarction: analysis and comparison of findings in 27 patients and 22 controls. Circulation 1980; 61: 786-90.
[118] Brosius FC III, Roberts WC. Significance of coronary arterial thrombus in transmural acute myocardial infarction. A study of 54 necropsy patients. Circulation 1981; 63: 810-6.
[119] Mann JM, Roberts WC. Fatal rupture of both left ventricular free wall and ventricular septum (double rupture) during acute myocardial infarction: analysis of 7 patients studied at necropsy. Am. J. Cardiol. 1987; 60: 722-4.
[120] Bertoncini G, Bertanelli F, Leone A. Coronary risk factors (CRF) in acute myocardial infarction (AMI) of elderly with and without hypertension. AJH 1999; 12: 197A-199A G002.
[121] Leone A. Are we able to prevent the death due to postinfarction cardiac rupture by early diagnosis and surgical treatment. Jpn. Heart J. 1991; 32: 635-44.
[122] Reinprecht F, Elmstahl S, Janzon L, André-Petersson L. Hypertension and changes of cognitive function in 81-year-old men: A 13- year follow-up of the population study “Men born in 1914”, Sweden. J. Hypertens. 2003; 21: 57-66.
[123] Norris JW, Zhu CZ, Bornstein NM, et al. Vascular risks of asymptomatic carotid stenosis. Stroke 1991; 22: 1485-90.
[124] Freedman BI, Iskander SS, Appel RG. The link between hypertension and nephrosclerosis. Am. J. Kidney Dis. 1995; 25: 207-21.
[125] Shiroma EJ, Lee MI. Physical activity and cardiovascular health. Lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 2010; 122: 743-52.
[126] Paffenbarger RS, Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause mortality, and longevity of college alumni. N. Engl. J. Med. 1986; 314: 605-13.
[127] Leon AS, Connett J, Jacobs DR, Rauramaa R. Leisure-time physical activity levels and risk of coronary heart disease and death. JAMA 1987; 258: 2388-95.
[128] Pekkanen J, Martin B, Nissinen A, et al. Reduction of premature mortality by high physical activity: a 20-year follow-up of middle-aged Finnish men. Lancet 1987; 1: 1473-7.
[129] Hespel P, Lijnen P, Fagard R, et al. Changes in erythrocyte sodium and plasma lipids associated with physical training. J. Hypertens. 1988; 6: 159-66.
[130] Tran ZV, Weltman A, Glass GV, Mood DP. The effects of exercise on blood lipids and lipoproteins: a meta-analysis of studies. Med. Sci. Sports Exerc. 1983; 15: 393-402
[131] Urata H, Tanabe Y, Kiyonaga A, et al. Antihypertensive and volume depleting effects of mild exercise on essential hypertension.

Chapter 8

[1] Havel RJ, Kane JP. Structure and metabolism of plasma lipoproteins. In: The Metabolic and Molecular Bases of Inherited Disease II, Scriver CR, Beaudet AL, Sly WS, Valle D eds, 7th Ed, Mc-Graw-Hill, New York, NY, USA, 1995; 1841 – 51.
[2] Kwiterovich PO Jr. The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82: Q13 – 21.
[3] Azizi F, Raiszadeh F, Salehi P, et al. Determinants of serum HDL-C level in a Tehran urban population: the Tehran Lipid and Glucose Study. Nutr. Metab. Cardiovasc. Dis. 2002; 12: 80 – 9.
[4] Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 2002; 91: 281 – 91.
[5] Tall AR. An overview of reverse cholesterol transport. Eur. Heart J. 1998; 19: A31 – 5.
[6] Block G, Dietrich M, Norkus EP, et al. Factors associated with oxidative stress in human population. Am. J. Epidemiol. 2002; 156: 274 – 85.
[7] Harrison D, Griendling KK, Landmesser U, et al. Role of oxidative stress in atherosclerosis. Am. J. Cardiol. 2003; 91: 7A – 11A.
[8] Barter P, Gotto AM, LaRosa JC, et al., for the treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl. J. Med. 2007; 357: 1301 – 10.
[9] Ross R. Factors influencing atherogenesis. In: Hurst’s The Heart 9th Edition, Alexander WR, Schlant RC, Fuster V, eds., McGraw-Hill, New York, NY, USA 1998; 1139 – 59.
[10] Gould SE, Ioannides G. Diseases of the Coronary Vessels. In: Pathology of the Heart and Blood Vessels 3rd Edition, Gould SE ed, Charles C Thomas, Springfield, Ill, USA 1968; 545- 600.
[11] Libby P. The vascular biology of atherosclerosis. In: Braunwald’s Heart Disease- A textbook of cardiovascular medicine 7th Edition, Zipes DP, Libby P, Bonow RO, Braunwald E eds., Elsevier Saunders, Philadelphia, Penn, USA 2005; 921 – 37.
[12] Falk E, Shah PK, Fuster V. Atherothrombosis and thrombosis-prone plaques. In: Hurst’s the Heart 11th Edition, Fuster V, Alexander WR, O’Rourke RA eds, McGraw-Hill, New York, NY, USA 2004; 1123 – 39.
[13] Fuster V, IP JHJ, Kiung Jang IK, Chesebro JH. Antithrombotic therapy in cardiac disease. In: Cardiology 7th Edition, Parmley WW and Chatterjee K eds, Lippincott- Raven, Philadelphia-New York, USA 1994; Vol 1 ( 25 ): 1 – 40.
[14] Varnava A. Coronary artery remodelling. Heart 1998; 79: 109 – 10.
[15] Marchand F (1904). In: Aschoff L, Introduction. Arteriosclerosis: A survey of the problem. Cowdry EV ed, McMillan, New York, NY, USA 1933; 1 – 18.
[16] Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868 – 74.
[17] Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Special report. Arterioscler. Thromb. 1994; 14: 840 – 56.
[18] Dartsch PC, Bauriedel G, Schinko I, et al. Cell constitution and characteristics of human atherosclerotic plaques selectively removed by percutaneous atherectomy. Atherosclerosis 1989; 80: 149 – 57.
[19] Simons M, Leclerc G, Safian RD, Isner JM, et al. Relation between activated smooth-muscle cells in coronary-artery lesions and restenosis after atherectomy. N. Engl. J. Med. 1993; 328: 608 – 13.
[20] Hofling B, Welsch U, Heimerl J, et al. Analysis of atherectomy specimens. Am. J. Cardiol. 1993; 72: E96 – 107.
[21] Rosenschein U, Ellis SG, Haudenschild CC, et al. Comparison of histopathologic coronary lesions obtained from directional atherectomy in stable angina versus acute coronary syndromes. Am. J. Cardiol. 1994; 73: 508 – 10.
[22] Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1898; 9 (Suppl 1): I-19 – 32.
[23] Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 1987; 316: 1371 – 5.
[24] Ross R, Wight TN, Strandness E, Thiele B. Human atherosclerosis, I: cell constitution and characteristics of advanced lesions of the superficial femoral artery. Am. J. Pathol. 1984; 114:79 – 93.
[25] Pouchlev A, Youroukova Z, Kiprov D. A study of changes in the number of mast cells in the human arterial wall during the stages of development of atherosclerosis. J. Atheroscler. Res. 1966; 6: 342 – 51.
[26] Pomerance A. Peri-arterial mast cells in coronary atheroma and thrombosis. J. Pathol. Bact. 1958; 76: 55 – 70.
[27] Glagov S, Zarins C, Giddens DP, Ku DN. Hemodynamics and atherosclerosis: insights and perspectives gained from studies of human arteries. Arch. Pathol. Lab. Med. 1988; 112: 1018 – 31.
[28] Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995; 92: 1355 – 74.
[29] Sandison AT. Persistence of sudanophilic lipid in sections of mummified tissue. Nature 1959; 183: 196 – 7.
[30] Ruffer MA. Histological studies on Egyptian Mummies. Mem à l’Institut Egyptien 1911; 6: Fasc. 3.
[31] Ruffer MA. On arterial lesions found in Egyptian mummies (1580 B.C. – 525 A.D.). J. Path. Bact. 1911; 15: 453 – 462.
[32] Shattock SG. A report upon the pathological condition of the aorta of King Memeptah. Proc. Roy. Soc. Med. (Pathological Section) 1909; 2: 122 – 7.
[33] Tapp E, Wildsmith K. The autopsy and endoscopy in the Leeds mummy. In: The Mummy Tale. David AR and Tapp E eds., Michael O’Mara Books, London, UK 1992; 132 – 53.
[34] Fejfar Z, Hlavackova L. Profiles in cardiology. Karl Rokitansky. Clin. Cardiol. 1997; 20: 816 – 8.
[35] Virchow R. Phlogose und thrombose im Gefassystem. In: Gesammelte Abhanndlugen zur wissensehaftlichen medizin. F Meidinger Sohn and Company, Frankfurt-am- Main, Germany, 1856; 458 – 521.
[36] Ignatowski AC. Influence of animal food on the organism of rabbits. Izv Imp voyenno-Med. Akad. Peter. 1908; 16: 154 – 73.
[37] Anitschkow NN, Chalatov S. Ueber experimentelle Choleserinsteatose und ihre bedeutung fur die entstehung einiger pathologischer prozesse. Zentralbl Allg Pathol. 1913; 24: 1 – 9.
[38] Anitschkow N. Ueber die veranderungen der kaninchenaorta bei experimenteller cholesterinsteatose. Beitr. Pathol. Anat. 1913; 56: 379 – 404
[39] Anitschkow N. Experimental atherosclerosis in animals. In: Arteriosclerosis, Cowdry EV ed, McMillan, New York, NY, USA, 1933; 271 – 322.
[40] Wolkoff K. Uber die atherosklerose der coronararterien des herzens. Beitr. Path. Anat. 1929; 82: 555 – 96.
[41] Gore I, Robertson WB, Hirst AE, et al. Geographic differences in the severity of aortic and coronary atherosclerosis: the U.S., Jamaica, W.L., South India, and Japan. Amer. J. Path. 1960; 36: 559 – 74.
[42] Zinserling WD. Untersuchungen uber atherosclerose. I. Uber die aortenverfettung bei kindern. Virchow Arch. Path. Anat. 1925; 225: 677 – 705.
[43] Holman RL, McGill HC Jr, Strong JP, Geer JC. The natural history of atherosclerosis. The early aortic lesions as seen in New Orleans in the middle of the 20th century. Am. J. Path. 1958; 34: 209 – 35.
[44] Stary HC, Blankenhorn DH, Chandler AB, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association. Special Report. Circulation 1992; 85: 391 – 405.
[45] Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993; 362: 801 – 9.
[46] Faggiotto A, Ross R, Harker L. Studies of hypercholesterolemia in the non-human primate: I. Changes that lead to fatty streak formation. Arteriosclerosis 1984; 4: 323 – 40.
[47] Tracy RE, Devaney K, Kissling G. Characteristics of the plaque under a coronary thrombus. Virchows Arch. A Pathol. Anat. Histopathol. 1985; 405: 411 – 27.
[48] Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br. Heart J. 1985; 53: 363 – 73.
[49] Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am. J. Cardiol. 1989; 63: E114 – 120.
[50] Falk E. Why do plaques rupture? Circulation 1992; 86: SIII 30 – 42.
[51] McGill HC Jr. Risk factors for atherosclerosis. Adv. Exp. Med. Biol. 1978; 104: 273 – 80.
[52] Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986; 25: 933 – 6.
[53] Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenes of the Multiple Risk Factor Intervention Trial ( MRFIT ). JAMA 1986; 256: 2823 – 8.
[54] Solberg LA, Strong JP. Risk factors and atherosclerotic lesions: a review of autopsy studies. Arteriosclerosis 1983; 3: 187 – 98.
[55] Powell KE, Thompson DP, Caspersen CJ, et al. Physical activity and the incidence of coronary heart disease. Annu. Rev. Public Health 1987; 8: 253-87.
[56] Berlin JA, Colditz JA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am. J. Epidemiol. 1990; 132: 612-28.
[57] Lakka TA, Venalainen JM, Rauramaa R, et al. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N. Engl. J. Med. 1994; 330: 1549-54.
[58] Hambrecht R, Niebauer J, Marburger C, et al. Various intensities of leisure time physical activity in patients with coronary artery disease: effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions. J. Am. Coll. Cardiol. 1993; 22: 468-77.
[59] Pekkanen J, Marti B, Nissinen A, et al. Reduction of premature mortality by high physical activity: a 20-year follow-up of middle-aged Finnish men. Lancet 1987; 1: 1473-7.
[60] Haskell WL. Exercise-induced changes in plasma lipids and lipoproteins. Prev. Med. 1984; 13: 23-36.
[61] Blair Sn, Kohl HW, Gordon NF, et al. How much physical activity is good for health? Annu. Rev. Public Health 1992; 13: 99-126.
[62] Roberts WC. An agent with lipid-lowering, antihypertensive, positive inotropic, negative chronotropic, vasodilating, diuretic, anorexigenic, weight-reducing, cathartic, hypoglycaemic, tranquilizing, hypnotic and antidepressive qualities (Editorial). Am. J. Cardiol. 1984; 53: 261-2.
[63] Gotto AM. Diet and cholesterol guidelines and coronary heart disease. Am. J. Cardiol. 1989; 13: 503-7.
[64] Kannel WB. Contributions of the Framingham Study to the conquest of coronary heart disease. Am. J. Cardiol. 1988; 62:1109-12.
[65] Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Arch. Intern. Med. 1988; 148: 36-69.
[66] Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am. J. Clin. Nutr. 1992; 56: 320-8.
[67] Marrugat J, Elosua R, Covas MI, et al., for the MARATHOM Investigators. Amount and intensity of physical activity, physical fitness, and serum lipids in men. Am. J. Epidemiol. 1996, 143: 562-9.
[68] Kendall DM, Sobel BE, Coulston AM, et al. The insulin resistance syndrome and coronary artery disease. Coron. Artery Dis. 2003; 14: 335 – 48.
[69] Reaven GM. The insulin resistance syndrome: Definition and dietary approaches to treatment. Annu. Rev. Nutr. 2005; 25: 391 – 406.
[70] Krolewski AS, Warram JH, Valsania P, et al. Evolving natural history of coronary artery disease in diabetes mellitus. Am. J. Med. 1991 ; 90 (Suppl 2A): 56S-61S.
[71] Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham Study. Ann. Intern. Med. 1977; 87: 393 – 7.
[72] Burchfield CM, Reed DM, Marcus EB, Strong JP, Hayashi T. Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions. An autopsy study from the Honolulu Heart Program. Am. J. Epidemiol. 1993; 137: 1328 – 40.
[73] Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 2). Circulation 1994; 89: 1329-445.
[74] Pan WH, Cedres LB, Liu K, et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am. J. Epidemiol. 1986; 123: 504-56.
[75] Leone A. Risk factors for coronary atherosclerosis. In: Coronary Circulation in Nonsmokers and Smokers, A Leone ed, Nova Biomedical, Nova Science publishers, Inc., New York, USA, 2008; pp: 131-7.
[76] Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: risk of cardiovascular disease and preventive measures. Curr. Pharm. Des 2003; 9: 2417-23.
[77] Bale GS, Entmacher PS. Estimated life expectancy of diabetics. Diabetes 1977; 26: 434-8.
[78] Oakley WG, Pike DD, Tattersall RB, Watkins PJ. Long-term diabetes. A clinical study of 92 patients after 40 years. Q. J. Med. 1974; 43: 145-56.
[79] Feskens EJ, Kromhout D. Cardiovascular risk factors and the 25-year incidence of diabetes mellitus in middle-aged men: the Zutphen Study. Am. J. Epidemiol. 1989; 130: 1101 – 8.
[80] Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and the incidence of type 2 diabetes. Diabetes 2002; 51: 3120 – 7.
[81] Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683 – 9.
[82] Reaven GM, Tsao PS. Insulin Resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? J. Am. Coll. Cardiol. 2003; 41: 1044 – 7.
[83] Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2909 – 16.
[84] Carnethon MR, Loria CM, Hill JO, et al. Risk factors for the metabolic syndrome: the Coronary Artery Risk Development in Young Adults (CARDIA) Study, 1985 – 2001. Diabetes Care 2004; 27: 2707 – 15.
[85] Yoo S, Niklas T, Baranowski T, et al. Comparison of dietary intakes associated with metabolic syndrome risk factors in young adults: the Bogalusa Heart Study. Am. J. Clin. Nutr 2004; 80: 841 – 8.
[86] Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356 – 9.
[87] Yoon YS, Oh SW, Baik HW, et al. Alcohol consumption and the metabolic syndrome in Korean adults: the 1998 Korean National Health and Nutrition Examination Survey. Am. J. Clin. Nutr. 2004; 80: 217 – 24.
[88] Barzilay JI, Abraham L, Heckbert SR, et al. The relation of inflammation to the development of glucose disorders in the elderly. Diabetes 2001; 50: 2384-9.
[89] Tuomi T, Groop LC, Zimmet PZ, et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993; 42: 359-62.
[90] Tumiolehto J, Zimmet P, Mackay IR, et al. Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease. Lancet 1994; 1383-5.
[91] Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, et al. Evidence of islet cell autoimmunità in elderly patients with type 2 diabetes. Diabetes 2000; 49: 32-8.
[92] Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of the acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-92.
[93] Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-8.
[94] Brzezinska B, Junik R, Kaminska A, et al. Factors associated with glucose metabolism disorders after kidney transplantation. Endokrynol. Pol. 2013; 64 (1): 21-5.
[95] Kato M, Hashimoto S, Ohta T, et al. Effect of training fitness on obesity, hypertension, hyperlipidemia and disorders in glucose metabolism. Nihon Koshu Eisei Zasshi 1993; 40 (12): 1129-38.
[96] Eriksson KF, Lindgärde F: Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 34:891–898, 1991.
[97] Pan X, Li G, Hu Y-H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-44.
[98] Kriska AM, Hanley AJ, Harris SB, Zinman B. Physical activity, physical fitness, and insulin and glucose concentrations in an isolated Native Canadian population experiencing rapid lifestyle change. Diabetes Care. 2001; 24 (10): 1787-92.

Chapter 9

[1] Kelly T, Yang W, Chen CS et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 32:1431-1437. Doi:10.1038/ijo.2008.102.PubMed:18607383.
[2] Obesity: preventing and managing the global epidemic. World Health Organization (WHO).
[3] Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity K.G.M.M. Alberti.
[4] Mokdad AH, Ford ES, Bowman BA et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:; 76-79. doi:10.1001/Jama.289.1.76. PubMed: 12503980.
[5] Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880. doi: 10.1038/nature05487. PubMed: 17167476.
[6] Karelis AD, St-Pierre DH, Conus F et al. Metabolic and body composition factors in subgroups of obesity : what do we know? J. Clin. Endocrinol. Metab. 2004; 89:2569-75.
[7] Sims EA. Are the persons who are obese, but metabolically healthy? Metabolism. 2001 Dec;50(12):1499-504.
[8] Karelis AD. Metabolically healthy but obese individuals. The Lancet, Volume 372, Issue 9646, Pages 1281 - 1283, 11 October 2008 doi:10.1016/S0140-6736(08)61531-7.
[9] Iacobelli G, Ribaudo MC, Zappaterreno A et al. Prevalence of uncomplicated obesity in an Italian obese population. Obes. Res. 2005; 13 1116-22.
[10] Stefan N. Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168: 1609-1616. Doi:10.1001/archinte. 168.15.1609. PubMed: 1869507.
[11] Aguilar-Salinas CA, Garcìa EG, Robles L et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J. Clin. Endocrinol. Metab. 2008; published online Aug 5. DOI:10.1210/jc.2007-2724.
[12] Brochu M, Tchernof A, Dionne IJ et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab, 2001, 86, 1020-5.
[13] Karelis AD, Faraj M, Bastard JP et al. The metabolically healthy, but obese individual presents a favorable inflammation profile. J. Clin. Endocrinol. Metab. 2005;90:
4145-50.
[14] Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes 1999;48:2210-14.
[15] Oflaz H, Ozbey N, Mantar F et al. Determination of endothelial function and early atherosclerotic changes in healthy obese women. Diabetes, Nutrition & Metabolism 2003, 16 (3):176-181.
[16] Guh DP, Zhang W, Bansback N et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 2009, 9:88.
[17] Berg, A.H., Scherer, P.E., 2005. Adipose tissue, inflammation, and cardiovascular disease. Circ. Res. 96, 939-949.
[18] Matsuzawa, Y., 2006. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med. 3,35-42.
[19] Phillips CM, Dillon C, Harrington JM et al. Defining Metabolically Healthy Obesity: Role of Dietary and Lifestyle Factors. PLoS One October 2013/volume 8/issue 10, Free PMC article.
[20] Pataky Z, Bobbioni –Harsch E, Golay A. Open questions about metabolically normal obesity. Int J Obes (Lond) 34 Suppl 2: S18-S23. Doi:10.1038/ijo.2010.235.
[21] Velho S., Paccaud F, Waeber G et al. Metabolically healthy obesity: different prevalences using different criteria. Eur. J. Clin. Nutr. 64: 1043-1051. Doi:10.1038/
ejcn.2010.114.Pub Med: 20628408.
[22] Brochu M, Tchernof A, Dionne IJ et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab, 2001, 86, 1020-5.
[23] Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004,30,569-572).
[24] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III) final report. Circulation, 2002,106,3143-421.
[25] Brochu M, Tchernof A, Dionne IJ et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J. Clin. Endocrinol. Metab., 2001, 86, 1020-5.
[26] DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. AM. J. Physiol. 1979 Sep;237(3):E214-23.
[27] Matthews DR, Hosker JP, Rudenski AS et al. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.”Diabetologia 28(7):412-9.
[28] Wallace TM, Levi JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27 (6):1487-95.
[29] Hermans MP, Levi JC, Morris RJ, Turner RC (1999). Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 48 (9): 1779-86.
[30] Hermans MP, Levi JC, Morris RJ, Turner RC (1999). Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42 (6): 678-87.
[31] Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112 (12) 1796- 1808 Hotamisligil GS Inflammation and metabolic disorders. Nature 2006;444 (7121) 860- 867.
[32] Pou KM, Massaro JM, Hoffmann U et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007;116 (11) 1234- 1241.
[33] Stefan N, Kantartzis K, Machann J et al. Identification and Characterization of Metabolically Benign Obesity in Humans. Arch. Intern. Med. 2008;168:1609-16.
[34] Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2006;2 (6) 335- 348.
[35] Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 2006;91 (12) 4753- 4761.
[36] Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr. Opin. Lipidol. 2005 Aug;16(4):421-7.
[37] Varman T.S., Zhen-Xiang L, Xianqin Qu et al. Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. J. Biol. Chem. 2004;279 (31) 32345- 32353.
[38] Targher G, Bertolini L, Padovani R et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30 (5) 1212- 1218.
[39] Targher G, Bertolini L, Padovani R et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006;29 (6) 1325- 1330.
[40] Villanova N, Moscatiello S, Ramilli S et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42 (2) 473- 480.
[41] Brea A, Mosquera D, Martìn E et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler. Thromb. Vasc. Biol. 2005;25 (5) 1045- 1050.
[42] Tolman KG, Fonseca V, Dalpiaz A et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30 (3) 734- 743.
[43] Osei–Hyiaman D, DePetrillo M, Pacher P et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet induced obesity. . Clin. Invest. 2005; 115(5):1298-1305.
[44] Stefan N, Machicao F, Staiger H et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia. 2005;48(11):2282-2291.
[45] Kantartzis K, Fritsche A, Machicao F et al. Upstream transcription factor 1 gene polymorphisms are associated with high antilipolytic insulin sensibility and show gene-gene interactions. J. Mol. Med.2007; 85 (1): 55-61.
[46] Perseghin G, Lattuada G, De Cobelli F et al. Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care. 2007;30(3):683-688.
[47] Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health. Obes. Res 2005; 6 (Suppl 2):5 1S-209S.
[48] Mc Laughlin T, Abbassi F, Lamendola C et al. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch. Intern. Med. 2007 Apr 9;167(7):642-8.
[49] Phillips CM (2013). Nutrigenetics and metabolic disease: current status and implications for personalized nutrition. Nutrients 5: 32-57. Doi:10.3390/nu5010032. PubMed: 23306188.
[50] Harrington J, Phillips CM. Nutrigenetics: Two world to understand type 2 diabetes. Curr Diab Rep 2013.
[51] Shin MJ, Hyun YJ, Kim JY et al. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int. J. Obes (Lond) 2006; 30:1529-1534.
[52] Arsenault BJ, Côté M, Cartier A et al. Effect of exercise training on cardiometabolic risk markers among sedentary, but metabolically healthy over-weight or obese postmenopausal women with elevated blood pressure. Atherosclerosis 2009; 207:530-533.
[53] Karelis AD, Messier V, Brochu M, Rabassa-Lhoret R. Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 2008; 51: 1752-1754.
[54] Kantartzis K, Machann J, Schick F et al. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia 2011; 54:864-868.
[55] Janiszewski PM, Ross R. Effects of weight loss among metabolically healthy obese men and women. Diabetes Care 2010; 33:1957-1959.

Chapter 10

[1] WHO. Lifestyle and Health. Social Science and Medicine 1986; 22: 117-24.
[2] Haskell WL. Primer in preventive cardiology. In: Pearson TA, Criqui MH, Luepker RV, et al. eds, American Heart Association, Dallas, USA, 1994; pp 173-87.
[3] Peto R, Lopez AD, Boreham J, et al. Mortality from smoking in developed countries: 1950-2000. Oxford; Oxford University Press 1994.
[4] Leone A. Biochemical markers of cardiovascular damage from tobacco smoke. Curr. Pharm. Des. 2005; 11: 2199-208.
[5] Wald NJ, Hackshaw AK. Cigarette smoking: an epidemiological overview. Br. Med. Bulletin 1996; 52: 3-11.
[6] George VA, Johnson P. Weight loss behaviors and smoking in College students of diverse ethnicity. Am. J. Health Behav. 2001; 25: 115-24.
[7] Grzywacz JG, Marks NF. Social inequalities and exercise during adulthood: Towards an ecological perspective. J. Health Soc. Behav. 2001; 42: 202-20.
[8] Johnson RA, Hoffmann JP. Adolescent cigarette smoking in the U.S. racial/ethnic subgroups: Findings from the National Education Longitudinal Study. 2000; J. Health Soc. Behav. 2000; 41: 392-407.
[9] Lindquist C, Cockerham WC, Hwang SS. Drinking patterns in the American Deep South. J. Studies Alcohol 1999; 60: 663-6.
[10] Cockerham WC. Health lifestyle theory and the convergence of Agency and structures. J. Health Soc. Behav. 2005; 46: 51-67.
[11] Leone A, Landini L, Leone A. Epidemiology and costs of hypertension-related disorders. Curr. Pharm. Des. 2011; 17: 2955-72.
[12] Robert SA, House JS. Socioeconomic inequalities in health: An enduring sociological problem. In : Handbook of Medical Sociology, 5th ed, Bird CE, Conrad P and Fremont AM eds, Prentice-Hall, Upper Saddle River, NJ, USA, 2000; pp: 79-97.
[13] Smaje C. Race, Ethnicity and Health. In: Handbook of Medical Sociology, 5th ed, Bird CE, Conrad P and Fremont AM eds, Prentice-Hall, Upper Saddle River, NJ, USA, 2000; pp:114-28.
[14] Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the National Conference on Cardiovascular Disease Prevention. Circulation 2000; 102 (25): 3137.
[15] Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345 (7): 479 -86.
[16] Ockene IS, Ockene JK. Barriers to lifestyle change, and the need to develop an integrated approach to prevention. Cardiol Clin 1996; 14: 159-69.
[17] Leone A. Relationship between cigarette smoking and other coronary risk factors in atherosclerosis: Risk of cardiovascular disease and preventive measures. Curr. Pharm. Des. 2003; 9: 2417-23.
[18] Leone O, Archilli E, Leone A Jr, Leone A. Smoking habit and alcohol consumption in schoolboys. In: Tobacco and Health, Slama K ed, Plenum Press, New York, USA, and London, UK, 1995; pp: 589-90.
[19] Abel T, Walter E, Niemann S, Weitkunat R: The Berne-Munich Lifestyle Panel. Sozial- und Praventivmedizin 1999; 44: 91-106.
[20] Wickrama KAS, Conger RD, Wallace LE, Elder GH Jr. The intergenerational transmission of health-risk behaviors: Adolescent lifestyles and gender moderating effects. J. Health Soc. Behav. 1999; 40: 258-72.
[21] Johnson PL. Gender differences in health-promoting lifestyle of African Americans. Public Health Nurs. 2005; 22 (2): 130-7.
[22] Biddle S, Goudas M, Page A. Social-psychological predictors of self-reported actual and intended physical activity in a university workforce sample. Br. J. Sports Med. 1994; 28: 160-3.
[23] Mosca L, McGillen C, Rubenfire M. Gender differences in barriers to lifestyle changes for cardiovascular disease prevention. J. Women Health 1998; 7 (6): 712-5.
[24] Sanchez-Villegas A, Delgado-Rodriguez M, Martinez-Gonzales MA, De Irala-Estévez J. Gender, age, socio-demographic and lifestyle factors associated with major dietary patterns in the Spanish Project SUN (Seguimiento Universidad de Navarra). Eur. J. Clin. Nutr. 2003; 57 (2): 285-92.
[25] Backett KC, Davison C. Lifecourse and lifestyle: The social and cultural location of health behaviours. Soc. Sci. Med. 1995; 40: 629-38.
[26] Leone A, Mori L, Bertanelli F, et al. Indoor passive smoking: Its effect on cardiac performance. Int. J. Cardiol. 1991; 8: 247-52.
[27] Enstrom JE, Breslow L. Lifestyle and reduced mortality among active California Mormons. Prev. Med. 2008; 46: 133-6.
[28] Cropper ML, Subramanian U. Public choices between lifesaving programs : how important are lives saved? The World Bank, in: Series 1497. August 31, 1995.
[29] Rainey CJ, McKeown RE, Sargent RG, Valois RF. Patterns of tobacco and alcohol use among sedentary, exercising, nonathletic and athletic youth. J. School Health 1996,

66:27-32.
[30] Rodriguez D, Audrain-McGovern J. Team sport participation and smoking: Analysis with general growth mixture modeling. J. Pediatr. Psychol. 2004, 29 (4)

: 299-308.
[31] Guo H, Reeder AI, McGee R, Darling H.. Adolescents’ leisure activities, parental monitoring and cigarette smoking – a cross-sectional study. Substance Abuse Treatment, Prevention, and Policy 2011, 6:12-
[32] Jansen I, LeBlanc AG. Systematic review of the health benefits of physical activity and fitness in school-aged children and youth. Int. J. Behav. Nutr. Physic. Activ. 2010; 7: 40, doi: 10.1186/1479-5868:7-40.
[33] Kohl HW, Craig CL, Lambert EV, et al. The pandemic of physical activity: global action for public health. Lancet 2012; 380: 294-305.
[34] Whitehead S, Biddle S. Adolescent girls’ perceptions of physical activity: a focus group study. Eur. Phys. Educ. Rev. 2008; 14: 243-62.
[35] Cannon CP, Braunwald E. Unstable angina and non-ST elevation myocardial infarction. In: Braunwald’s Heart Disease, A Textbook of Cardiovascular Medicine 7 ed , Zipes DP, Libby P, Bonow RO, Braunwald E eds., Elsevier Saunders, Philadelphia, PA, USA, 1980; pp:1243-79.
[36] Morrow DA, Gersh BJ, Braunwald E. Chronic coronary artery disease. In: Braunwald’s Heart Disease, A Textbook of Cardiovascular Medicine 7 ed , Zipes DP, Libby P, Bonow RO, Braunwald E eds., Elsevier Saunders, Philadelphia, PA, USA, 1980; pp:1281-354..
[37] Leone A. Passive smoking causes cardiac alterations in post-MI subjects. Int. J. Smoking Cessation 1996; 3: 42-3.
[38] Leone A, Bertanelli F, Mori L, et al. Ventricular arrhythmias by passive smoking in patients with preexisting myocardial infarction. J. Am. Coll. Cardiol. 1992; 3: 256A.
[39] WHO. The World Health Report 2002: Reducing risks, promoting healthy life. Geneva WHO; 2002.
[40] Murray CJL, Lopez AD. The global burden of disease. Cambridge, MA, Harvard School of Public Health, 1996.
[41] NIH Consensus Development Panel on Physical Activity and Cardiovascular Health. Physical activity and cardiovascular health. JAMA. 1996;276:241–6.
[42] Morris JN, Everitt MG, Pollard R, et al. Vigorous exercise in leisure-time: protection against coronary heart disease. Lancet. 1980;2:1207–10.
[43] Sesso HD, Paffenbarger RS Jr, Lee MI. Physical activity and coronary heart disease in men. Circulation 2000; 102: 975-80.
[44] Colucci WS, Braunwald E. Pathophysiology of heart failure. In : Braunwald’s Heart Disease, A Textbook of Cardiovascular Medicine 7 ed , Zipes DP, Libby P, Bonow RO, Braunwald E eds., Elsevier Saunders, Philadelphia, PA, USA, 1980; pp: 509-38.
[45] Kannel WB. Incidence and epidemiology of heart failure. Heart Fail. Rev. 2000; 5 (2): 167-73.
[46] Landini L, Lambelet P, Taccola D, et al. Blood pressure and cardiovascular comorbidity in chronic heart failure of ageing. JCH 2013; 15 (Suppl 1): A 63-4.
[47] Morris JN, Marr JW, Clayton DG. Diet and heart: a postscript. BMJ 1977; 2: 1370.
[48] Garcia-Palmieri MR. Prescription of physical activity for the promotion of cardiovascular. Editorial. Cardiology Section of the University of Puerto Rico School of Medicine 2008; pp 361-2.
[49] Garcia-Palmieri MR, Costas R, Cruz-Vidal M, et al. Increased physical activity: A protective factor against heart attack in Puerto Rico. Am. J. Cardiol. 1982; 50: 749-55.
[50] Costas R, Garcia-Palmieri MR, Nazario E, Sorlie PD. Relation of lipids, weight and physical activity to incidence of coronary disease: The Puerto Rico Heart Study. Am. J. Cardiol. 1978; 42: 653-8.
[51] Cresp CJ, Garcia-Palmieri MR, Perez-Perdomo R, et al. The relationship of physical activity and body weight with all-cause mortality. Results from the Puerto Rico Heart Program. Ann. Epidemiol. 2002; 12: 543-52.
[52] Speiser W, Langer W, Pschaick A, et al. Increased blood fibrinolytic activity after physical exercise: comparative study in individuals with different sporting activities and in patients after myocardial infarction taking part in a rehabilitation sports program. Thromb. Res. 1988; 51(5):543-55.

Chapter 11

[1] Garcia-Palmieri MR, Costas R, Cruz-Vidal M, et al. Increased physical activity: A protective factor against heart attacks in Puerto Rico. Am. J. Cardiol. 1982; 50: 749-55.
[2] Beckers PJ, Denollet J, Possemiers NM, et al. Maintaining physical fitness of patients with chronic heart failure: a randomized controlled trial. Eur. J. Cardiovasc. Prev. Rehabil. 2010; 17(6): 660-7.
[3] McHenry MM. Medical screening of patients with coronary heart disease: criteria for entry into exercise conditioning programs. Am. J. Cardiol. 1974; 33: 752-6.
[4] Coats AJS, Adamopoulos S, Meyer TE, et al. Effects of physical training in chronic heart failure. 1990; 335: 63-6.
[5] Hambrecht R, Niebauer J, Fiehn E, et al. Physical training in patients with stable chronic heart failure: effects on cardiorespiratory fitness and ultrastructural abnormalities of leg muscles. J. Am. Coll. Cardiol. 1995; 25(6):1239-49.
[6] Wise FM, Patrick JM. Cardiac rehabilitation outcomes in women with chronic heart failure: mood, fitness, and exercise safety. J. Cardiopulm. Rehabil. Prev. 2012; 32(2):78-84.
[7] Corbin CB, Pangrazi RP, Franks DB. Definitions: Health, fitness and physical activity. ERIC, Number ED 470696, ISBN: N/A, ISSN: N/A, Pages: 11.
[8] Williams PT. Walking and running produce similar reductions in cause-specific disease mortality in hypertensives. Hypertension 2013, 62. 485-91.
[9] Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int. J. Obes. Relat. Metab. Disord. 1998;22:39-47.








You have not viewed any product yet.